WO2002030944A2 - Fluorescent nucleobase conjugates having anionic linkers - Google Patents
Fluorescent nucleobase conjugates having anionic linkers Download PDFInfo
- Publication number
- WO2002030944A2 WO2002030944A2 PCT/US2001/031822 US0131822W WO0230944A2 WO 2002030944 A2 WO2002030944 A2 WO 2002030944A2 US 0131822 W US0131822 W US 0131822W WO 0230944 A2 WO0230944 A2 WO 0230944A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- conjugate
- moiety
- dye
- linker
- anionic
- Prior art date
Links
- 0 *CC(C(C1)F)OC1[n](cc1C#Cc(cc2)ccc2C#CCOP(O)(OCCNC(c(cc2C(O)=O)ccc2C(c(ccc(O)c2)c2O2)=C(C=C3)C2=C(CNC(c2ccc(CN)cc2)=O)C3=O)=O)=O)c(N=C(N)N2)c1C2=O Chemical compound *CC(C(C1)F)OC1[n](cc1C#Cc(cc2)ccc2C#CCOP(O)(OCCNC(c(cc2C(O)=O)ccc2C(c(ccc(O)c2)c2O2)=C(C=C3)C2=C(CNC(c2ccc(CN)cc2)=O)C3=O)=O)=O)c(N=C(N)N2)c1C2=O 0.000 description 2
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/06—Pyrimidine radicals
- C07H19/10—Pyrimidine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H19/00—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof
- C07H19/02—Compounds containing a hetero ring sharing one ring hetero atom with a saccharide radical; Nucleosides; Mononucleotides; Anhydro-derivatives thereof sharing nitrogen
- C07H19/04—Heterocyclic radicals containing only nitrogen atoms as ring hetero atom
- C07H19/16—Purine radicals
- C07H19/20—Purine radicals with the saccharide radical esterified by phosphoric or polyphosphoric acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C40—COMBINATORIAL TECHNOLOGY
- C40B—COMBINATORIAL CHEMISTRY; LIBRARIES, e.g. CHEMICAL LIBRARIES
- C40B40/00—Libraries per se, e.g. arrays, mixtures
Definitions
- the present invention relates to fluorescent dye compounds, and to conjugates and uses thereof.
- the invention also relates to fluorescent polynucleotide conjugates having improved electrophoretic mobilities.
- Electrophoresis provides convenient methods for analyzing polynucleotides.
- polynucleotides can be separated on the basis of length, due to differences in electrophoretic mobility.
- a matrix such as crosslinked polyacrylamide
- polynucleotides typically migrate at rates that are inversely proportional to polynucleotide length, due to size-dependent obstruction by the crosslinked matrix.
- polynucleotides tend to migrate at substantially the same rates because of their substantially identical mass to charge ratios, so that it is difficult to distinguish different polynucleotides based on size alone.
- distinguishable electrophoretic mobilities can be obtained in free solution using polynucleotides that contain different charge/mass ratios, e.g., by attaching to the polynucleotides a polymer or other chemical entity having a charge/mass ratio that differs from that ofthe polynucleotides alone (e.g., see US Patent No. 5,470,705).
- detection can usually be accomplished using a single detectable label, such as a radioisotope or fluorophore.
- detectable label such as a radioisotope or fluorophore.
- DNA sequencing it is now conventional to use two or more (usually four) different fluorescent labels to distinguish sequencing fragments that terminate with one of the four standard nucleotide bases (A, C, G and T, or analogs thereof).
- Such labels are usually introduced into the sequencing fragments using suitably labeled extension primers (dye-primer method) or by performing primer extension in the presence of nonextendable nucleotides that contain unique labels (Sanger dideoxy terminator method). Electrophoresis of the labeled products generates ladders of fragments that can be detected on the basis of elution time or band position.
- Anomalous migration patterns may also occur for polynucleotide fragments that contain a detectable label, due to interactions between the label and one or more bases in the polynucleotide. Such interactions can be particularly problematic when the interactions are sequence-dependent, so that different-sequence fragments having the same-lengths may have significantly different mobilities. This phenomenon can be inconvenient for sequencing, especially in automated sequencing methods. Accordingly, there is a need for labeled compounds and methods of use to improve electrophoretic performance.
- the present invention provides a conjugate comprising a dye-labeled nucleobase ofthe form: (1) B-L-D, wherein B is a nucleobase, L is an anionic linker, and D comprises at least one fluorescent dye, or (2) B-L1-D1-L2-D2, wherein B is a nucleobase, LI and L2 are linkers such that at least one of LI and L2 is an anionic linker, and Dl and D2 are members of a fluorescent donor/acceptor pair, such that one of Dl and D2 is a donor dye capable of absorbing light at a first wavelength and emitting excitation energy in response thereto, and the other of Dl and D2 is an acceptor dye capable of absorbing the excitation energy emitted by the donor dye and fluorescing at a second wavelength in response thereto.
- Each anionic linker may contain one or more anionic groups, such as a sulfonic acid moiety, a sulfate monoester, an anionic phosphate, an anionic phosphonate, or a carboxylic acid.
- L, LI or L2 contains a phosphate diester moiety whose phosphorus atom is located within a chain of linker atoms (bridging position) or can be a substituent attached to a chain of linker atoms (non-bridging position).
- the linker contains a monoanionic phosphonate ester which can be located within the linker chain or attached to the linker chain. Other embodiments are described further herein.
- one of LI and L2 can be a nonanionic linker.
- LI is an anionic linker and L2 is non-anionic.
- D1-L2-D2 may comprise structure (a), (b) or (c) below: (a) -Dl-R 2 ⁇ Z ⁇ C(0)R22R28-D2
- R 21 is -C 5 alkyldiyl
- Z ⁇ is NH, S, or O
- R 22 is ethenediyl, ethynediyl, 1,3- butadienediyl, 1,3-butadiynediyl, a 5- or 6-membered ring having at least one unsaturated bond or a fused ring structure having at least one unsaturated bone
- R 28 is a bond or spacer group (a linking segment) that links R22 to Dl or D2.
- Fluorescent dyes used in accordance with the invention can include any fluorescent compound suitable for the purposes ofthe present invention.
- each dye comprises a conjugated, resonance-delocalized or aromatic ring system that absorbs light at a first wavelength and emits light at a second wavelength in response thereto.
- the dyes can be selected independently from any of a variety of classes of fluorescent compounds, such as xanthene, rhodamine, dibenzorhodamine, fluorescein, [8,9]benzophenoxazine, cyanine, phthalocyanine, squaraine, or bodipy dye.
- the invention includes a labeled nucleoside triphosphate comprising a conjugate of the type described herein.
- the labeled nucleoside triphosphate is not 3'-extendable.
- the labeled nucleoside triphosphate can be a 2',3'-dideoxynucleotide or S'-fluoro ⁇ ' ⁇ '-dideoxynucleotide.
- the labeled nucleoside triphosphate is extendable and contains a 3'- hydroxyl group.
- the invention includes a polynucleotide comprising a conjugate of the type discussed herein.
- the conjugate is located in a 3' terminal nucleotide subunit of a polynucleotide, such that the subunit may be extendable or nonextendable.
- the conjugate is located on a non-terminal nucleotide subunit.
- the invention provides a mixture comprising a plurality of different-sequence polynucleotides, wherein at least one polynucleotide contains a conjugate as described herein.
- the mixture comprises at least two different-sequence polynucleotides which each contain a different conjugate to identify the attached polynucleotide.
- the mixture comprises four classes of polynucleotides, wherein the polynucleotides in each class terminate with a different terminator subunit type that contains a distinct nucleobase-dye conjugate to identify the polynucleotides in that class.
- the invention also includes a method of identifying one or more polynucleotide(s).
- one or more labeled different-sequence polynucleotides are formed such that each different-sequence polynucleotide contains a unique conjugate as described herein.
- the one or more labeled different-sequence polynucleotides are separated by electrophoresis on the basis of size, and one or more different-sequence polynucleotides are identified on the basis of electrophoretic mobilities and fluorescence properties.
- the invention also provides a method of forming a labeled polynucleotide strand, the method comprising reacting together (i) a duplex polynucleotide comprising a 3'- extendable strand hybridized to a complementary template strand having a 5' overhang, (ii) a template-dependent polymerase enzyme, and (iii) a labeled nucleoside triphosphate containing a conjugate as described herein, under conditions effective to form a labeled polynucleotide containing the conjugate.
- the labeled nucleoside triphosphate is nonextendable.
- the labeled nucleoside triphosphate is extendable.
- the invention also provides a method of sequencing a target polynucleotide sequence.
- four classes of polynucleotides are formed which are complementary to a target polynucleotide sequence, by template-dependent primer extension, wherein the polynucleotides in each class terminate with a different terminator subunit type that contains a distinct nucleobase-dye conjugate to identify the polynucleotides in that class.
- the resultant polynucleotides are separated on the basis of size to obtain a mobility pattern from which the sequence of the target polynucleotide sequence can be determined.
- the kit comprises at least one labeled nucleoside triphosphate comprising a conjugate described herein.
- the kit may also include one or more of the following components: a 3'-extendable primer, a polymerase enzyme, one or more 3' extendable nucleotides which are not labeled with conjugate, and/or a buffering agent.
- the kit includes at least one labeled nucleoside triphosphate that is nonextendable.
- the kit comprises four different labeled nucleoside triphosphates which are complementary to A, C, T and G, and each of which contains a distinct conjugate as described herein.
- the labeled nucleoside triphosphates are nonextendable. In another embodiment, the labeled nucleoside triphosphates are extendable ribonucleoside triphosphates. In another embodiment, the kit comprises at least one labeled, nonextendable nucleoside triphosphate comprising a conjugate described herein, and one or more of the following components: a 3'-extendable primer, a polymerase enzyme, and/or a buffering agent.
- Figs. 1A-18B and 22A-22B illustrate exemplary synthetic protocols for preparing various conjugates in accordance with the invention.
- Figs. 19A and 19B show electropherograms of sequencing ladders terminating with a first set of terminators (ddG).
- Figs. 20A and 20B show electropherograms of sequencing ladders terminating with a second set of terminators different from those in Figs. 1 A and IB (ddA).
- Figs. 21 A and 21B show electropherograms of sequencing ladders terminating with a third set of terminators (ddA). Detailed Description
- the present invention is directed to novel dye compounds and dye conjugates that have various advantageous properties.
- the invention has general application in the areas of fluorescent nucleic acid analysis, e.g., automated DNA or RNA sequencing, fragment analysis, detection of nucleic acid amplification products, detection of probe hybridization in hybridization arrays, diagnostic tests, and the like.
- the invention provides polynucleotides having more consistent size-dependent electrophoretic mobilities, such that sequence-dependent anomalies are reduced or eliminated.
- the invention finds application in automated sequencing methods which rely on uniform, size-dependent electrophoretic mobilities to determine whether low peak signals should be included or discarded, and whether overlapping peaks represent fragments of the same length.
- the invention is also useful in sequencing methods that involve the formation of 3' dye-labeled sequencing fragments.
- the invention can be used in polynucleotide detection and identification methods that rely on absolute or relative migration times or migration distances for polynucleotide identification.
- Alkyl refers to a saturated or unsaturated, branched, straight-chain or cyclic monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane, alkene or alkyne.
- Typical alkyl groups include, but are not limited to, methyl; ethyls such as ethanyl, ethenyl, ethynyl; propyls such as propan- 1-yl, propan-2-yl, cyclopropan-1-yl, prop- 1 -en- 1-yl, prop-l-en-2-yl, prop-2-en-l-yl, cycloprop-1-en-l-yl; cycloprop-2-en-l-yl, prop- 1-yn- 1-yl , prop-2-yn-l-yl, etc.; butyls such as butan-1-yl, butan-2-yl, 2-methyl-propan-l-yl, 2-methyl-propan-2-yl, cyclobutan-1-yl, but- 1 -en- 1-yl, but-l-en-2-yl, 2-methyl-prop-l-en-yl, but-2-en-l-yl ,
- alkanyl alkenyl
- alkynyl alkynyl
- alkanyl refers to a saturated branched, straight-chain or cyclic alkyl radical derived by the removal of one hydrogen atom from a single carbon atom of a parent alkane.
- Typical alkanyl groups include, but are not limited to, methanyl; ethanyl; propanyls such as propan-1-yl, propan-2-yl (isopropyl), cyclopropan-1-yl, etc.; butyanyls such as butan-1-yl, butan-2-yl (sec-butyl), 2-methyl-propan-l-yl (isobutyl), 2-methyl-pro ⁇ an-2-yl (t-butyl), cyclobutan-1-yl, etc.; and the like.
- the alkanyl groups are C 6 ) alkanyl.
- Alkenyl refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon double bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkene.
- the radical may be in either the cis or trans conformation about the double bond(s).
- Typical alkenyl groups include, but are not limited to, ethenyl; propenyls such as prop- 1 -en- 1-yl , ⁇ rop-l-en-2-yl, prop-2-en-l-yl, prop- 2-en-2-yl, cycloprop-1-en-l-yl; cycloprop-2-en-l-yl ; butenyls such as but- 1 -en- 1-yl, but-1- en-2-yl, 2-methyl-prop-l-en-l-yl, but-2-en-l-yl , but-2-en-l-yl, but-2-en-2-yl, buta-1,3- dien-1-yl, buta-l,3-dien-2-yl, cyclobut-1-en-l-yl, cyclobut-l-en-3-yl, cyclobuta-l,3-dien-l- yl, etc.; and the like.
- alkenyl group is (C 2 -C 6 ) alkenyl.
- Alkynyl refers to an unsaturated branched, straight-chain or cyclic alkyl radical having at least one carbon-carbon triple bond derived by the removal of one hydrogen atom from a single carbon atom of a parent alkyne.
- Typical alkynyl groups include, but are not limited to, ethynyl; propynyls such as prop- 1-yn- 1-yl , prop-2-yn-l-yl, etc.; butynyls such as but- 1-yn- 1-yl, but-l-yn-3-yl, but-3-yn-l-yl , etc.; and the like, hi preferred embodiments, the alkynyl group is (C 2 -C 6 ) alkynyl.
- Alkyldiyl refers to a saturated or unsaturated, branched, straight-chain or cyclic divalent hydrocarbon radical derived by the removal of one hydrogen atom from each of two different carbon atoms of a parent alkane, alkene or alkyne, or by the removal of two hydrogen atoms from a single carbon atom of a parent alkane, alkene or alkyne.
- the two monovalent radical centers or each valency of the divalent radical center can form bonds with the same or different atoms.
- Typical alkyldiyls include, but are not limited to methandiyl; ethyldiyls such as ethan-l,l-diyl, ethan-l,2-diyl, ethen-l,l-diyl, ethen-l,2-diyl; propyldiyls such as propan-l,l-diyl, propan-l,2-diyl, propan-2,2-diyl, propan-l,3-diyl, cyclopropan-l,l-diyl, cyclopropan-l,2-diyl, prop-l-en-l,l-diyl, prop-l-en-l,2-diyl, pro ⁇ -2- en-l,2-diyl, prop-l-en-l,3-diyl, cycloprop-l-en-l,2-diyl, cycloprop-2-en
- alkanyldiyl alkenyldiyl and/or alkynyldiyl
- the alkyldiyl group is ( -C ⁇ ) alkyldiyl.
- saturated acyclic alkanyldiyl radicals in which the radical centers are at the terminal carbons e.g., methandiyl (methano); ethan-l,2-diyl (ethano); propan-l,3-diyl (propano); butan-l,4-diyl (butano); and the like (also refened to as alkylenos, defined infra).
- Alkyleno refers to a straight-chain alkyldiyl radical having two terminal monovalent radical centers derived by the removal of one hydrogen atom from each of the two terminal carbon atoms of straight-chain parent alkane, alkene or alkyne.
- Typical alkyleno groups include, but are not limited to, methano; ethylenos such as ethano, etheno, ethyno; propylenos such as propano, prop[l]eno, propa[l,2]dieno, prop[l]yno, etc.; butylenos such as butano, but[l]eno, but[2]eno, buta[l,3]dieno, but[l]yno, but[2]yno, but[l,3]diyno, etc.; and the like. Where specific levels of saturation are intended, the nomenclature alkano, alkeno and/or alkyno is used. In preferred embodiments, the alkyleno group is ( -C ⁇ ) alkyleno.
- Heteroalkyl, Heteroalkanyl, Heteroalkenyl, Heteroalkanyl, Heteroalkyldiyl and Heteroalkyleno refer to alkyl, alkanyl, alkenyl, alkynyl, alkyldiyl and alkyleno radicals, respectively, in which one or more of the carbon atoms are each independently replaced with the same or different heteroatomic groups.
- Acyclic Heteroatomic Bridge refers to a divalent bridge in which the backbone atoms are exclusively heteroatoms.
- Typical acyclic heteroatomic bridges include, but are not limited to, any of the various heteroatomic groups listed above, either alone or in combinations.
- Parent aromatic ring system refers to an unsaturated cyclic or polycyclic ring system having a conjugated ⁇ electron system.
- parent aromatic ring system fused ring systems in which one or more of the rings are aromatic and one or more ofthe rings are saturated or unsaturated, such as, for example, indane, indene, phenalene, etc.
- Typical parent aromatic ring systems include, but are not limited to, aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, as- indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like.
- Aryl refers to a monovalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a parent aromatic ring system.
- Typical aryl groups include, but are not limited to, radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, ⁇ s-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleia
- Aryldiyl refers to a divalent aromatic hydrocarbon radical derived by the removal of one hydrogen atom from each of two different carbon atoms of a parent aromatic ring system or by the removal of two hydrogen atoms from a single carbon atom of a parent aromatic ring system.
- the two monovalent radical centers or each valency of the divalent center can form bonds with the same or different atom(s).
- Typical aryldiyl groups include, but are not limited to, divalent radicals derived from aceanthrylene, acenaphthylene, acephenanthrylene, anthracene, azulene, benzene, chrysene, coronene, fluoranthene, fluorene, hexacene, hexaphene, hexalene, ⁇ xs-indacene, s-indacene, indane, indene, naphthalene, octacene, octaphene, octalene, ovalene, penta-2,4-diene, pentacene, pentalene, pentaphene, perylene, phenalene, phenanthrene, picene, pleiadene, pyrene, pyranthrene, rubicene, triphenylene, trinaphthalene, and the like
- the aryldiyl group is (C 5 -C 14 ) aryldiyl, with (C 5 - 0 ) being even more preferred.
- the most preferred aryldiyl groups are divalent radicals derived from benzene and naphthalene, especially phena-l,4-diyl, naphfha-2,6-diyl and naphfha-2,7-diyl.
- Aryleno refers to a divalent bridge radical having two adjacent monovalent radical centers derived by the removal of one hydrogen atom from each of two adjacent carbon atoms of a parent aromatic ring system. Attaching an aryleno bridge radical, e.g. benzeno, to a parent aromatic ring system, e.g. benzene, results in a fused aromatic ring system, e.g. naphthalene. The bridge is assumed to have the maximum number of non-cumulative double bonds consistent with its attachment to the resultant fused ring system.
- R 1 when taken alone is hydrogen, or when taken together with R 2 is (C 5 -C 1 ) aryleno; and R 2 , when taken alone is hydrogen, or when taken together with R 1 is (C 5 -C 14 ) aryleno.
- aryleno When R taken together with R is Cio aryleno (naphthaleno), the resultant compound is anthracene or phenanthrene.
- Typical aryleno groups include, but are not limited to, aceanfhryleno, acenaphthyleno, acephenanfhryleno, anthraceno, azuleno, benzeno (benzo), chryseno, coroneno, fluorantheno, fluoreno, hexaceno, hexapheno, hexaleno, ⁇ s-indaceno, 5-indaceno, indeno, naphthaleno (haphtho), octaceno, octapheno, octaleno, ovaleno, penta- 2,4-dieno, pentaceno, pentaleno, pentapheno, peryleno, phenaleno
- the involved bridging carbon atoms are denoted in brackets, e.g., [l,2]benzeno ([l,2]benzo), [l,2]naphthaleno,
- Arylaryl refers to a monovalent hydrocarbon radical derived by the removal of one hydrogen atom from a single carbon atom of a ring system in which two or more identical or non-identical parent aromatic ring systems are joined directly together by a single bond, where the number of such direct ring junctions is one less than the number of parent aromatic ring systems involved.
- Typical arylaryl groups include, but are not limited to, biphenyl, triphenyl, phenyl-naphthyl, binaphthyl, biphenyl-naphthyl, and the like. When the number of carbon atoms comprising an arylaryl group is specified, the numbers refer to the carbon atoms comprising each parent aromatic ring.
- arylaryl is an arylaryl group in which each aromatic ring comprises from 5 to 14 carbons, e.g., biphenyl, triphenyl, binaphthyl, phenylnaphthyl, etc.
- each parent aromatic ring system of an arylaryl group is independently a (C 5 -C ⁇ ) aromatic, more preferably a (C 5 - C 10 ) aromatic.
- arylaryl groups in which all of the parent aromatic ring systems are identical, e.g., biphenyl, triphenyl, binaphthyl, trinaphthyl, etc.
- Biaryl refers to an arylaryl radical having two identical parent aromatic systems joined directly together by a single bond.
- Typical biaryl groups include, but are not limited to, biphenyl, binaphthyl, bianthracyl, and the like.
- the aromatic ring systems are (C 5 -C 14 ) aromatic rings, more preferably (C 5 -C 10 ) aromatic rings.
- a particularly preferred biaryl group is biphenyl.
- Arylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with an aryl radical.
- Typical arylalkyl groups include, but are not limited to, benzyl, 2-phenylefhan-l-yl, 2-phenylethen-l-yl, naphthylmethyl, 2-naphthylethan-l-yl, 2-naphthylethen-l-yl, naphthobenzyl, 2-naphthophenylethan-l-yl and the like.
- arylalkyl group is (C 6 -C 20 ) arylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the arylalkyl group is ( -C ⁇ ) and the aryl moiety is (C 5 -C 14 ).
- the arylalkyl group is (C 6 -C 13 ), e.g., the alkanyl, alkenyl or alkynyl moiety ofthe arylalkyl group is (C] . -C 3 ) and the aryl moiety is (C 5 -C 10 ).
- Parent Heteroaromatic Ring System refers to a parent aromatic ring system in which one or more carbon atoms (and any necessary associated hydrogen atoms) are each independently replaced with the same or different heteroatom. Typical heteratoms to replace the carbon atoms include, but are not limited to, N, P, O, S, Si, etc. Specifically included within the definition of "parent heteroaromatic ring systems” are fused ring systems in which one or more rings are aromatic and one or more of the rings are saturated or unsaturated, such as, for example, arsindole, chromane, chromene, indole, indoline, xanthene, etc.
- Typical parent heteroaromatic ring systems include, but are not limited to, arsindole, carbazole, ⁇ -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pynolizine, quinazoline, quinoline, quinolizine, quinoxaline, tetrazole,
- Heteroaryl refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a parent heteroaromatic ring system.
- Typical heteroaryl groups include, but are not limited to, radicals derived from acridine, arsindole, carbazole, ⁇ -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyri
- the heteroaryl group is a 5-14 membered heteroaryl, with 5-10 membered heteroaryl being particularly preferred.
- the most prefened heteroaryl radicals are those derived from parent heteroaromatic ring systems in which any ring heteroatoms are nitrogens, such as imidazole, indole, indazole, isoindole, naphthyridine, pteridine, isoquinoline, phthalazine, purine, pyrazole, pyrazine, pyridazine, pyridine, pynole, quinazoline, quinoline, etc.
- Heteroaryldiyl refers to a divalent heteroaromatic radical derived by the removal of one hydrogen atom from each of two different atoms of a parent heteroaromatic ring system or by the removal of two hydrogen atoms from a single atom of a parent heteroaromatic ring system.
- the two monovalent radical centers or each valency of the single divalent center can form bonds with the same or different atom(s).
- Typical heteroaryldiyl groups include, but are not limited to, divalent radicals derived from acridine, arsindole, carbazole, ⁇ -carboline, chromane, chromene, cinnoline, furan, imidazole, indazole, indole, indoline, indolizine, isobenzofuran, isochromene, isoindole, isoindoline, isoquinoline, isothiazole, isoxazole, naphthyridine, oxadiazole, oxazole, perimidine, phenanthridine, phenanthroline, phenazine, phthalazine, pteridine, purine, pyran, pyrazine, pyrazole, pyridazine, pyridine, pyrimidine, pyrrole, pyrrolizine, quinazoline, quinoline, quinolizine, qui
- the heteroaryldiyl group is 5-14 membered heteroaryldiyl, with 5-10 membered being particularly preferred.
- the most preferred heteroaryldiyl groups are divalent radicals derived from parent heteroaromatic ring systems in which any ring heteroatoms are nitrogens, such as imidazole, indole, indazole, isoindole, naphthyridine, pteridine, isoquinoline, phthalazine, purine, pyrazole, pyrazine, pyridazine, pyridine, pyrrole, quinazoline, quinoline, etc.
- Heteroaryleno refers to a divalent bridge radical having two adjacent monovalent radical centers derived by the removal of one hydrogen atom from each of two adjacent atoms of a parent heteroaromatic ring system. Attaching a heteroaryleno bridge radical, e.g. pyridino, to a parent aromatic ring system, e.g. benzene, results in a fused heteroaromatic ring system, e.g., quinoline. The bridge is assumed to have the maximum number of non- cumulative double bonds consistent with its attachment to the resultant fused ring system.
- R when taken alone is hydrogen, or when taken together with R is 5-14 membered heteroaryleno; and R 2 , when taken alone is hydrogen, or when taken together with R 1 is 5-14 membered heteroaryleno.
- R and R are each hydrogen, the resultant compound is benzene.
- R taken together with R is a 6-membered heteroaryleno (e.g., pyridino)
- the resultant compound is isoquinoline, quinoline or quinolizine.
- R 1 taken together with R 2 is a 10-membered heteroaryleno (e.g., isoquinoline)
- the resultant compound is, e.g., acridine or phenanthridine.
- Typical heteroaryleno groups include, but are not limited to, acridino, carbazolo, ⁇ -carbolino, chromeno, cinnolino, furano, imidazolo, indazoleno, indoleno, indolizino, isobenzofurano, isochromeno, isoindoleno, isoquinolino, isothiazoleno, isoxazoleno, naphthyridino, oxadiazoleno, oxazoleno, perimidino, phenanthridino, phenanthrolino, phenazino, phthalazino, pteridino, purino, pyrano, pyrazino, pyrazoleno, pyridazino, pyridino, pyrimidino, pyrroleno, pyrrolizino, quinazolino, quinolino,
- the heteroaryleno group is 5-14 membered heteroaryleno, with 5-10 membered being even more prefened.
- the most prefened heteroaryleno radicals are those derived from parent heteroaromatic ring systems in which any ring heteroatoms are nitrogens, such as imidazolo, indolo, indazolo, isoindolo, naphthyridino, pteridino, isoquinolino, phthalazino, purino, pyrazolo, pyrazino, pyridazino, pyridino, pyrrolo, quinazolino, quinolino, etc.
- Heteroaryl-Heteroaryl refers to a monovalent heteroaromatic radical derived by the removal of one hydrogen atom from a single atom of a ring system in which two or more identical or non-identical parent heteroaromatic ring systems are joined directly together by a single bond, where the number of such direct ring junctions is one less than the number of parent heteroaromatic ring systems involved.
- Typical heteroaryl-heteroaryl groups include, but are not limited to, bipyridyl, tripyridyl, pyridylpurinyl, bipurinyl, etc. When the number of ring atoms are specified, the numbers refer to the number of atoms comprising each parent heteroatomatic ring systems.
- 5-14 membered heteroaryl-heteroaryl is a heteroaryl-heteroaryl group in which each parent heteroaromatic ring system comprises from 5 to 14 atoms, e.g., bipyridyl, tripyridyl, etc.
- each parent heteroaromatic ring system is independently a 5-14 membered heteroaromatic, more preferably a 5-10 membered heteroaromatic.
- Also prefened are heteroaryl-heteroaryl groups in which all of the parent heteroaromatic ring systems are identical.
- heteroaryl-heteroaryl radicals are those in which each heteroaryl group is derived from parent heteroaromatic ring systems in which any ring heteroatoms are nitrogens, such as imidazole, indole, indazole, isoindole, naphthyridine, pteridine, isoquinoline, phthalazine, purine, pyrazole, pyrazine, pyridazine, pyridine, pyrrole, quinazoline, quinoline, etc.
- Biheteroaryl refers to a heteroaryl-heteroaryl radical having two identical parent heteroaromatic ring systems joined directly together by a single bond.
- Typical biheteroaryl groups include, but are not limited to, bipyridyl, bipurinyl, biquinolinyl, and the like.
- the heteroaromatic ring systems are 5-14 membered heteroaromatic rings, more preferably 5-10 membered heteroaromatic rings.
- the most prefened biheteroaryl radicals are those in which the heteroaryl groups are derived from a parent heteroaromatic ring system in which any ring heteroatoms are nitrogens, such as biimidazolyl, biindolyl, biindazolyl, biisoindolyl, binaphthyridinyl, bipteridinyl, biisoquinolinyl, biphthalazinyl, bipurinyl, bipyrazolyl, bipyrazinyl, bipyridazinyl, bipyridinyl, bipyrrolyl, biquinazolinyl, biquinolinyl, etc.
- Heteroarylalkyl refers to an acyclic alkyl radical in which one of the hydrogen atoms bonded to a carbon atom, typically a terminal or sp 3 carbon atom, is replaced with a heteroaryl radical. Where specific alkyl moieties are intended, the nomenclature heteroarylalkanyl, heteroarylakenyl and/or heterorylalkynyl is used. In preferred embodiments, the heteroarylalkyl group is a 6-20 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety of the heteroarylalkyl is 1-6 membered and the heteroaryl moiety is a 5-14-membered heteroaryl.
- the heteroarylalkyl is a 6-13 membered heteroarylalkyl, e.g., the alkanyl, alkenyl or alkynyl moiety is 1-3 membered and the heteroaryl moiety is a 5-10 membered heteroaryl.
- Substituted refers to a radical in which one or more hydrogen atoms are each independently replaced with the same or different substituent(s).
- Nucleobase means a nifrogen-containing heterocyclic moiety capable of forming Watson-Crick type hydrogen bonds with a complementary nucleobase or nucleobase analog, e.g. a purine, a 7-deazapurine, or a pyrimidine.
- Typical nucleobases are the naturally occurring nucleobases adenine, guanine, cytosine, uracil, thymine, and analogs of naturally occurring nucleobases, e.g.
- Nucleoside means a compound comprising a nucleobase linked to a C-l' carbon of a ribose sugar or analog thereof.
- the ribose or analog may be substituted or unsubstituted.
- Substituted ribose sugars include, but are not limited to, those riboses in which one or more of the carbon atoms, preferably the 3'-carbon atom, is substituted with one or more of the same or different substituents such as -R, -OR, -NRR or halogen (e.g., fluoro, chloro, bromo, or iodo), where each R group is independently -H, C]-C 6 alkyl or C 3 -C 14 aryl.
- substituents such as -R, -OR, -NRR or halogen (e.g., fluoro, chloro, bromo, or iodo)
- riboses particularly prefened riboses are ribose, 2'-deoxyribose, 2 , ,3'-dideoxyribose, 3'-haloribose (such as 3'-fluororibose or 3'-chlororibose) and 3'-alkylribose.
- the nucleobase is A or G
- the ribose sugar is attached to the N 9 -position of the nucleobase.
- the nucleobase is C, T or U
- the pentose sugar is attached to the N 1 -position of the nucleobase (Kornberg and Baker, DNA Replication, 2 nd Ed., Freeman, San Francisco, CA, (1992)).
- ribose analogs include arabinose, 2'-O-methyl ribose, and locked nucleoside analogs (e.g., WO 99/14226), for example, although many other analogs are also known in the art.
- Nucleotide means a phosphate ester of a nucleoside, either as an independent monomer or as a subunit within a polynucleotide. Nucleotide triphosphates are sometimes denoted as "NTP", “dNTP” (2'-deoxypentose) or “ddNTP” (2',3'-dideoxypentose) to particularly point out the structural features ofthe ribose sugar.
- Nucleotide 5'-triphosphate refers to a nucleotide with a triphosphate ester group at the 5' position.
- the triphosphate ester group may include sulfur substitutions for one or more phosphate oxygen atoms, e.g. ⁇ -thionucleotide 5'-triphosphates.
- Polynucleotide and “oligonucleotide”, which are used interchangeably herein, refer to linear polymers of natural nucleotide monomers or analogs thereof, including for example, double- and single-stranded deoxyribonucleotides, ribonucleotides, ⁇ -anomeric forms thereof, and the like.
- a polynucleotide may be composed entirely of deoxyribonucleotides, ribonucleotides, or analogs thereof, or may contain blocks or mixtures of two or more different monomer types. Usually nucleoside monomers are linked by phosphodiester linkages.
- Polynucleotide and oligonucleotides containing non-phosphodiester linkages are also contemplated.
- Polynucleotide and oligonucleotide also encompass polymers that contain one or more non-naturally occurring monomers and/or intersubunit linkages, such as peptide nucleic acids (PNAs, e.g., polymers comprising a backbone of amide- linked N-(2-aminoethyl)-glycine subunits to which nucleobases are attached via the non-amide backbone nitrogens. See Nielsen et al., Science 254:1497-1500 (1991)).
- PNAs peptide nucleic acids
- Polynucleotides typically range in size from a few monomeric units, e.g. 8-40, to several thousand monomeric units. Whenever a polynucleotide is represented by a sequence of letters, such as "ATGCCTG,” it will be understood that the nucleotides are in 5'->3' order from left to right and that "A” denotes deoxyadenosine, “C” denotes deoxycytidine, “G” denotes deoxyguanosine, and “T” denotes thymidine, unless otherwise noted.
- A denotes deoxyadenosine
- C denotes deoxycytidine
- G denotes deoxyguanosine
- T denotes thymidine, unless otherwise noted.
- Nucleotide subunit or “polynucleotide subunit” refers to a single nucleotide or nucleotide analog within a polynucleotide or polynucleotide analog.
- Phosphate analog refers to an analog of phosphate wherein one or more of the oxygen atoms is replaced with a non-oxygen moiety.
- Exemplary phosphate analogs including phosphorothioate, phosphorodithioate, phosphoroselenoate, phosphorodiselenoate, phosphoro- anilothioate, phosphotriester, phosphoranilidate, phosphoramidate, alkylphosphonates such as methylphosphonates, boronophosphates.
- Linker refers to a moiety that links a dye to a substrate such as an oligonucleotide, or links one dye to another dye (e.g., links a donor to an acceptor dye).
- "Enzymatically incorporatable” means that a nucleotide is capable of being enzymatically incorporated onto the terminus, e.g. 3' terminus, of a polynucleotide chain, or internally through nick-translation of a polynucleotide chain, through action of a template- dependent or template-independent polymerase enzyme.
- a nucleotide-5 '-triphosphate is an example of an enzymatically incorporatable nucleotide.
- Enzymatically extendable or “3' extendable” means a nucleotide or polynuceotide that is capable of being appended to a nucleotide or polynucleotide by enzyme action.
- a polynucleotide containing a 3' hydroxyl group is an example of an enzymatically extendable polynucleotide.
- Terminator means an enzymatically incorporatable nucleotide which prevents subsequent incorporation of nucleotides to the resulting polynucleotide chain and thereby halts polymerase-mediated extension.
- Typical terminators lack a 3'-hydroxyl substituent and include 2',3'-dideoxyribose, 2',3'-didehydroribose, and 2',3'-dideoxy-3'-haloribose, e.g. 3'- deoxy-3'-fluoro-ribose or 2',3'-dideoxy-3'-fluororibose, for example.
- a ribofuranose analog can be used, such as 2',3'-dideoxy- ⁇ -D-ribofuranosyl, ⁇ -D- arabinofuranosyl, 3'-deoxy- ⁇ -D-arabinofuranosyl, 3'-amino-2',3'-dideoxy- ⁇ -D- ribofuranosyl, and 2',3'-dideoxy-3'-fluoro- ⁇ -D-ribofuranosyl (see, for example, Chidgeavadze et al., Nucleic Acids Res., 12: 1671-1686 (1984), and Chidgeavadze et al. FEB. Lett., 183: 275-278 (1985)). Nucleotide terminators also include reversible nucleotide terminators (Metzker et al. Nucleic Acids Res., 22(20):4259 (1994)).
- Nonextendable or “3' nonextendable” refers to the fact that a terminator is incapable, or substantially incapable, of being extended in the 3' direction by a template-dependent DNA or RNA polymerase.
- “Spectrally resolvable” means that two or more dyes have emission bands that are sufficiently distinct, i.e., sufficiently non-overlapping, that they can be disinguished on the basis of a unique fluorescent signal generated by each dye.
- a compound mentioned in this disclosure contains a positive or negative charge
- a suitable counterion that balances the positive or negative charge
- exemplary positively charged counterions include, without limitation, H + , NH 4 + , Na + , K + , Mg 24" , trialkylammonium (such as triethylammonium), tetraalkylammonium (such as tetraethylammonium), and the like.
- exemplary negatively charged counterions include, without limitation, carbonate, bicarbonate, acetate, chloride, and phosphate, for example.
- resonance structures may be shown herein, such structures are intended to include all other possible resonance structures.
- compositions that comprise at least one dye-labeled nucleobase of the type described herein.
- compositions include not only nucleobase-dye conjugates as independent molecules, but also as nucleosides, nucleotides and polynucleotides containing such conjugates.
- a dye-labeled nucleobase of the invention has the form B-L-D, wherein B is a nucleobase, L is an anionic linker, and D is a fluorescent dye.
- Nucleobase B may be any moiety capable of forming Watson-Crick hydrogen bonds with a complementary nucleobase or nucleobase analog, as set forth in the Definition section above.
- B is a nitrogen-containing heterocyclic moiety such as a 7- deazapurine, purine, or pyrimidine nucleotide base.
- B is uracil, cytosine, 7-deazaadenine, or 7-deazaguanosine.
- the linker is usually attached to the 8-position of the purine.
- B is a 7-deazapurine
- the linker to the dye is usually attached to the 7-position of the 7-deazapurine.
- Fluorescent dye D may be any fluorescent dye which is suitable for the purposes of the invention.
- the fluorescent dye comprises a resonance-delocalized system or aromatic ring system that absorbs light at a first wavelength and emits fluorescent light at a second wavelength in response to the absorption event.
- fluorescent dyes can be selected from any of a variety of classes of fluorescent compounds, such as xanthenes, rhodamines, fluoresceins, cyanines, phthalocyanines, squaraines, and bodipy dyes.
- the dye is a xanthene-type dye, which contains a fused three- ring system ofthe form:
- This parent xanthene ring may be unsubstituted (i.e., all substituents are H) or may be substituted with one or more of a variety of the same or different substituents, such as described below.
- the dye contains a parent xanthene ring having the general structure:
- a 1 is OH or NH 2 and A 2 is O or NH 2 + .
- a 1 is OH and A 2 is O
- the parent xanthene ring is a fluorescein-type xanthene ring.
- A is NH 2 and A is NH
- the parent xanthene ring is a rhodamine-type xanthene ring.
- the parent xanthene ring is a rhodol-type xanthene ring.
- one or both nitrogens of A 1 and A 2 (when present) and/or one or more of the carbon atoms at positions Cl, C2, C4, C5, C7, C8 and C9 can be independently substituted with a wide variety of the same or different substituents.
- typical substituents include, but are not limited to, -X, -R, -OR, -SR, -NRR, perhalo (d ⁇ C 6 ) alkyl,-CX 3 , -CF 3 , -CN, -OCN, -SCN, -NCO, -NCS, -NO, -NO 2 , -N 3 , - S(O) 2 O " , -S(O) 2 OH, -S(O) 2 R, -C(O)R, -C(O)X, -C(S)R, -C(S)X, -C(O)OR, -C(O)O ⁇ - C(S)OR, -C(O)SR, -C(S)SR, -C(O)NRR, -C(S)NRR and -C(NR)NRR, where each X is independently a halogen (preferably -F or Cl) and each R is
- Cl and C2 substituents and/or the C7 and C8 substituents can be taken together to form substituted or unsubstituted buta[l,3]dieno or (C 5 -C 2 Q) aryleno bridges.
- substituents which do not tend to quench the fluorescence of the parent xanthene ring are preferred, but in some embodiments quenching substituents may be desirable.
- Substituents that tend to quench fluorescence of parent xanthene rings are electron-withdrawing groups, such as -NO 2 , -Br, and -I.
- C9 is unsubstituted.
- C9 is substituted with a phenyl group.
- C9 is substituted with a substituent other than phenyl.
- a 1 is NH 2 and/or A 2 is NH 2 +
- these nitrogens can be included in one or more bridges involving the same nitrogen atom or adjacent carbon atoms, e.g., (C ⁇ -C 1 ) alkyldiyl, (CrC 12 ) alkyleno, 2-12 membered heteroalkyldiyl and/or 2-12 membered heteroalkyleno bridges.
- Exemplary parent xanthene rings include, but are not limited to, rhodamine-type parent xanthene rings and fluorescein-type parent xanthene rings.
- the dye contains a rhodamine-type xanthene dye that includes the following ring system:
- one or both nitrogens and/or one or more ofthe carbons at positions Cl, C2, C4, C5, C7 or C8 can be independently substituted with a wide variety of the same or different substituents, as described above for the parent xanthene rings, for example.
- Exemplary rhodamine-type xanthene dyes include, but are not limited to, the xanthene rings of the rhodamine dyes described in US Patents 5,936,087, 5,750,409, 5,366,860, 5,231,191, 5,840,999, 5,847,162, and 6,080,852 (Lee et al.), PCT Publications WO 97/36960 and WO 99/27020, Sauer et al, J.
- the dye comprises a fluorescein-type parent xanthene ring having the structure:
- fluorescein-type parent xanthene ring depicted above one or more of the carbons at positions Cl, C2, C4, C5, C7, C8 and C9 can be independently substituted with a wide variety of the same or different substituents, as described above for the parent xanthene rings.
- Exemplary fluorescein-type parent xanthene rings include, but are not limited to, the xanthene rings of the fluorescein dyes described in US Patents 4,439,356, 4,481,136, 5,188,934, 5,654,442, and 5,840,999, WO 99/16832, and EP 050684.
- fluorescein-type parent xanthene ring also included within the definition of "fluorescein-type parent xanthene ring" are the extended xanthene rings of the fluorescein dyes described in US Patents 5,750,409 and 5,066,580.
- the dye comprises a rhodamine dye, which comprises a rhodamine-type xanthene ring in which the C9 carbon atom is substituted with an orthocarboxy phenyl substituent (pendent phenyl group).
- rhodamine dyes which comprises a rhodamine-type xanthene ring in which the C9 carbon atom is substituted with an orthocarboxy phenyl substituent (pendent phenyl group).
- orthocarboxyfluoresceins Such compounds are also refened to herein as orthocarboxyfluoresceins.
- a particularly prefened subset of rhodamine dyes are 4,7,-dichlororhodamines.
- Typical rhodamine dyes include, but are not limited to, rhodamine B, 5-carboxyrhodamine, rhodamine X (ROX), 4,7-dichlororhodamine X (dROX), rhodamine 6G (R6G), 4,7-dichlororhodamine 6G, rhodamine 110 (R110), 4,7- dichlororhodamine 110 (dRllO), tetramefhyl rhodamine (TAMRA) and 4,7-dichloro- teframethylrhodarnine (dTAMRA).
- the dye is a 4,7-dichloro- orthocarboxyrhodamine.
- the dye comprises a fluorescein dye, which comprises a fluorescein-type xanthene ring in which the C9 carbon atom is substituted with an orthocarboxy phenyl substituent (pendent phenyl group).
- a prefened subset of fluorescein- type dyes are 4,7,-dichlorofluoresceins.
- Typical fluorescein dyes include, but are not limited to, 5-carboxyfluorescein (5-FAM), 6-carboxyfluorescein (6-FAM).
- the dye is a 4,7-dichloro-orfhocarboxyfluorescein.
- the dye can be a cyanine, phthalocyanine, squaraine, or bodipy dye, such as described in the following references and references cited therein: Patent No. 5,863,727 (Lee et al.), 5,800,996 (Lee et al.), 5,945,526 (Lee et al.), 6,080,868 (Lee et al.), 5,436,134 (Haugland et al.), US 5,863,753 (Haugland et al.), 6,005,113 (Wu et al.), and WO 96/04405 (Glazer et al.).
- the designation -1 or -2 is placed after an abbreviation of a particular dye, e.g., HEX-1.
- the "-1" and “-2" designations indicate that a particular 5- or 6-carboxy dye isomer being used.
- the 1 and 2 isomers are defined by order of elution (the 1 isomer elutes before the 2 isomer) of free dye in a reverse-phase chromatographic separation system utilizing a C-8 column and an elution gradient of 15% acetonitrile/85% 0.1 M triethylammonium acetate to 35% acetonitrile / 65% 0.1 M triethylammonium acetate.
- Anionic linker L is designed to have an overall negative charge.
- this negative charge is provided by one or more negatively charged groups in the linker.
- the anionic linker contains a positively charged group (e.g., bridging or nonbridging amino groups), then the linker must also contain a sufficient number of negatively charged groups to ensure that the total negative charge in the linker exceeds the total positive charge.
- the linker contains no positively charged groups.
- the linker may contain one, two, or more net negative charges which may be provided by one, two, or more negatively charged groups.
- the linker contains a single negative charge.
- the linker contains two negative charges which may be provided by a single group or two groups.
- the overall charge of the linker at pH 9 can be at least -1, -2, -3, or greater. Preferably, the overall charge of the linker at pH 9 is at least -1.
- anionic groups can include groups with a pK a ⁇ 10, such as nitrophenolate, thiolate, phenylthiolate, fluorinated alkyl alcohol (e.g., perfluoro hydroxymethyl or perfluoro hydroxyethyl), sulfonimides, and squarates.
- groups with a pK a ⁇ 10 such as nitrophenolate, thiolate, phenylthiolate, fluorinated alkyl alcohol (e.g., perfluoro hydroxymethyl or perfluoro hydroxyethyl), sulfonimides, and squarates.
- anionic groups witiiin a linker can be classified in various ways. First, anionic groups can be divided between bridging and non-bridging groups, depending on whether an anionic group is within the chain of linker atoms (a bridging anionic group) or is outside the chain of linker atoms (a non-bridging group).
- the invention contemplates linkers that contain one or more bridging anionic groups, one or more divalent anionic groups, and combinations thereof.
- Examples of groups that provide a double negative charge at pH 9 include phosphate monoester (non- bridging) and phosphonic acid of the form (-CH 2 PO 3 2" ). Accordingly, the invention contemplates linkers that contain singly charged anionic groups, doubly charged anionic groups, and combinations thereof.
- a linker between B and D will have a linker chain length of from about 4 to about 30 linker chain atoms, and typically from 4 to 20 linker chain atoms, although shorter and longer linkers may also be used.
- linker chain length typically from about 4 to about 30 linker chain atoms, and typically from 4 to 20 linker chain atoms, although shorter and longer linkers may also be used.
- the junction between a nucleobase B and linker L can be located at any suitable position on the nucleobase.
- the attachment site on the nucleobase is selected so as not to interfere with or eliminate the H-bonding capability ofthe nucleobase with respect to a complementary nucleobase.
- B includes a purine nucleobase the linker is usually attached to the N-8-position of the purine.
- B includes a 7-deazapurine nucleobase the linker is usually attached to the N-7-position of the 7-deazapurine.
- B includes a pyrimidine base the linkage is attached to the C-5-position ofthe pyrimidine.
- a purine or 7-deazapurine is usually attached to a sugar moiety via the N-9-position ofthe purine or deazapurine
- a pyrimidine is usually attached to a sugar moiety via the N-l -position ofthe pyrimidine.
- the particular entity by which a linker is connected to a nucleobase can be any chemical group that is suitable for the purposes of the present invention.
- suitable chemical groups are known.
- the terminal chemical group in the linker that is covalently attached to the nucleobase can be an acetylene moiety (-C ⁇ C-), and often is a propargyl moiety (-C ⁇ CCH 2 -), since such linkage moieties tend to be particularly compatible with a variety of polymerase enzymes used for primer extension.
- non-acetylenic chemical groups are also contemplated. Examples of suitable terminal groups for attachment to a nucleobase can be found in the following exemplary references: Table 1
- linker L and dye moiety D can be located at any suitable position on the dye moiety, preferably so that the fluorescent properties of the dye are not adversely affected.
- the linker can be joined to any available carbon atom, or to one of the nitrogen atoms in a rhodamine-type xanthene ring.
- the substituent positions on the pendent phenyl ring are also available, particularly the positions which are para to C9 of the xanthene ring (5 position), or para to the ortho carboxyl group (6 position).
- the particular chemical group by which a linker is connected to a nucleobase can be any chemical group that is suitable for the purposes of the present invention.
- a variety of chemical groups and points of attachment on various dyes can be found, for example, in US Patents 5,654,442 and 5,188,934 (Menchen et al.), 6,020,481 (Benson et al.), 5,800,996 (Lee et al.), 6,025,505 (Lee et al.), 5,821,356 (Khan et al.), 5,770,716 (Khan et al.), 6,088,379 (Benson et al), 6,051,719 (Benson et al), 6,096,875 (Khan et al.), 6,080,868 (Lee et al.), US patent application Ser.
- the linker is attached to the dye via a 5-carboxyphenyl (para to the xanthene C9 carbon atom) or 6-carboxyphenyl group (meta to the xanthene C9 carbon atom).
- the linker is preferably attached to a 4-carbon atom or 5-carbon atom on the xanthene ring.
- the linker is attached to the 3 or 6- nitrogen atom of the xanthene ring.
- the dye-labeled nucleobase of the invention may also have the form B-L1-D1-L2- D2, wherein B is a nucleobase, LI and L2 are linkers such that at least one of LI and L2 is an anionic linker, and Dl and D2 are members of a fluorescent donor/acceptor pair.
- Dl is a donor dye
- D2 is an acceptor dye
- D2 is a donor dye
- Dl is an acceptor dye.
- the donor dye and acceptor dye have different (non-identical) spectral properties.
- the donor and acceptor may have the same type of aromatic ring structure (e.g., when both the donor and acceptor are fluorescein dyes, or both are rhodamine dyes), different spectral properties can arise for the donor and acceptor due to the nature of the substituents on each one.
- the donor dye is effective to enhance the intensity of fluorescence emission ofthe acceptor dye relative to the intensity that would be observed in the absence of the donor dye under the same conditions.
- Conjugates of this form may be referred to herein as "FRET probes", “FRET-labeled conjugates” or FRET-labeled nucleotides because upon excitation of the donor dye, the conjugate can undergo nonradiative fluorescence resonance energy transfer from the donor to the acceptor, such that the acceptor dye can then emit fluorescent light at a second wavelength in response thereto.
- the donor dye and acceptor dye can be any fluorescent dye, and are each preferably fluorescent aromatic dyes.
- the donor and acceptor dye, taken separately, can be a xanthene, rhodamine, dibenzorhodamine, fluorescein, [8,9]benzophenoxazine, cyanine, phthalocyanine, squaraine, or bodipy dye.
- the donor and acceptor dyes can be linked together using any of a variety of attachment sites on each dye.
- Dl can be linked via its xanthene ring (preferably via C4)) to the pendent phenyl ring of D2 (e.g., via a 5- or 6-carboxy group on the pendent phenyl group).
- This is referred to as a head to tail arrangement.
- the positions ofthe connections can be reversed, such that D2 is linked via its xanthene ring to the pendent phenyl ring of Dl (another example of a head to tail anangement).
- Dl and D2 can be connected tail to tail, via their pendent phenyl rings, or head to head, via their xanthene rings, for example.
- At least one of LI and L2 is an anionic linker.
- the properties of such anionic linkers are generally as discussed for anionic linker L above.
- LI is an anionic linker and L2 is a non-anionic linker.
- L2 any of a variety of non-anionic linkers can be used to connect Dl to D2.
- D1-L2-D2 may comprise one of structures (a), (b) or (c) below:
- R 21 is Q-C 5 alkyldiyl
- Z ⁇ is NH, S, or O
- R 22 is an alkene, diene, alkyne, or a 5- or 6-membered ring having at least one unsaturated bond or a fused ring structure
- R 28 is a bond or spacer group. Details and examples of such inter-dye linkers can be found in US Patent 5,800,996, for example.
- R 22 is ethenediyl, ethynediyl, 1,3- butadienediyl, or 1,3-butadiynediyl.
- LI is a non-anionic linker and L2 is an anionic linker.
- any of a variety of non-anionic linkers can be used to connect B to Dl.
- Descriptions of exemplary nonanionic linkers can be found in the references in Table 1 above.
- LI can be or contain any ofthe following non-limiting examples:
- non-anionic linkers encompass linkers that are either charge-neutral or are positively charged.
- Charge-neutral linkers refer to linkers that either contain no charged groups at pH 7 (i.e., has no charged group having a pKa between 6 and 8), or contain equal numbers of positively and negatively charged groups which cancel to provide a net charge of zero.
- a positively charged linker is positively charged at pH 7, e.g., due to the presence of an ammonium ion or imidazole ion, for example.
- a non-anionic linker is a charge-neutral linker.
- the charge-neutral linker contains no charged groups at pH 7.
- LI and L2 are both anionic linkers
- the structures of LI and L2 can be the same or different, and the anionic group(s) in the linkers can also be the same or different. Further guidance regarding conjugate structures in accordance with the invention is provided below.
- conjugates of the invention may be prepared by any suitable synthetic method.
- conjugates of the invention are formed using a modular approach in which a nucleobase (which may be provided in the form of a nucleoside or nucleotide containing the nucleobase, for example), a first dye, a second dye (if present), and one or more linkers or linker precursors, are combined in serial and/or parallel steps to produce the desired labeled product.
- Example 1 describes a synthetic method for preparing a labeled nucleotide in accordance with the invention, which contains a (i) first dye linked via C-8 of a 7- deazaadenine nucleobase by an anionic linker that contains a phosphate diester moiety within the chain of linker atoms, and (ii) a second dye linked to the first dye by a charge- neutral (non-anionic) linker.
- the linker between the nucleobase and the first dye contains 13 linker chain atoms.
- the linker between the first and second dyes contains 10 linker atoms.
- a bifunctional linker moiety 7 is formed in several steps by first reacting a cyclic phosphoramidite 1 with methyl glycolate 2, followed by oxidation, to form phosphate compound 3. After removal of a methyl group from the phosphate to produce 4, and deprotection of the amino and carboxyl groups to produce compound 5, an Fmoc protecting group is attached to the amine to produce carboxylic acid 6. Activation of the carboxylic acid with N-hydroxysuccinimide (NHS) produces ester 7, which is a versatile linker synthon. Ester 7 is then reacted with 7-aminopropargyl-7-deazaadenosine triphosphate 8 to form compound 9.
- NHS N-hydroxysuccinimide
- dye compound 11 was prepared by reacting -aminomethylbenzoic acid with Fmoc acid chloride to form Fmoc protected !?-aminomethylbenzoic acid.
- NHS ester product was reacted with 4'-aminomethyl-6-carboxyfluorescein to produce the expected amide adduct.
- the 6-carboxyl group was then reacted with NHS to produce dye compound 11.
- Reaction of compounds 10 and 11 produced adduct 12, in which an anionic (phosphate-containing) linker is formed fully between the fluorescein dye and the nucleobase.
- the resultant free amine compound 13 was reacted with rhodamine NHS ester 14 to form dye-labeled nucleotide 15.
- Example 2 An alternative method for preparing compound 10 used in Example 1 is provided in Example 2.
- This Example describes a synthetic approach in which a linker synthon 19 containing a phosphate monoester is prepared for reaction with a nucleoside containing an iodinated nucleobase (7-iodo-7-deazaadenine).
- 3 -amino- 1 -propyne 16 is reacted with methyl glycolate 2 to form the expected amide product 17.
- Reaction of 17 with cyclic phosphoramidite 1 followed by oxidation affords phosphate triester 18.
- resultant phosphodiester compound 19 is reacted with iodo-nucleoside 20 to afford adduct 21.
- the 5 '-hydroxyl group of the nucleoside can be converted to a triphosphate group by reaction with phosphorous oxychloride to form dichloromonophosphate 22, followed by addition of pyrophosphate to provide nucleoside triphosphate 23. Removal of the trifluoracetyl protecting group from the terminal amine nitrogen provides synthon 10.
- Example 4 describes synthesis of a synthetic method for preparing a FRET-labeled nucleotide which contains a (i) first dye linked to a 7-deazaadenine nucleobase by a charge- neutral (non-anionic) linker, and (ii) a second dye linked to the first dye by an anionic linker that contains a monoanionic sulfonic acid moiety.
- the linker between the nucleobase and the first dye contains 5 linker chain atoms.
- the linker between the first and second dyes contains 10 linker atoms.
- j ⁇ -aminomethylbenzoic acid 24 is reacted with sulfuric acid to form the meta-sulfonated product 25.
- Reaction with Fmoc- succinimide affords Fmoc protected amine 26, which is then reacted with N- hydroxysuccinimide to form NHS ester 27.
- dye-labeled nucleoside triphosphate 30 can be prepared by reacting aminopropargyl nucleoside triphosphate 8 with dye intermediate 28 (a fluorescein dye containing a trifluoroacetyl- protected 4'-aminomethyl group and an NHS ester of a 6-carboxyl group) to afford dye- labeled nucleotide 29, followed by removal of the trifluoroacetyl (TFA) group to afford amine compound 30.
- Reaction of NHS ester 27 and compound 30 affords Fmoc-protected compound 31.
- resultant amine compound 32 is reacted with dye NHS ester 14 to afford dye-labeled nucleotide 33. It can be seen that the linker between the first and second dyes contains a sulfonic acid group which is attached to a benzene moiety in the linker chain.
- Example 5 a protocol is described for preparing a labeled nucleotide in which first and second dyes of a donor-acceptor pair are linked by a phosphate-containing linker, and the donor dye is linked to a nucleobase by a charge-neutral linker.
- This nucleotide product differs from the product of Example 1 since the anionic phosphate linker is located between the first dye and the nucleobase.
- the product of Example 5 also differs from the product of Example 4 since the anionic linker between the two dyes contains a phosphate monoester in the linker chain, rather than a sulfonic acid group attached to the linker chain.
- the compounds also differ in the lengths of some ofthe linkers.
- aminopropargyl nucleotide 8 is combined with dye NHS ester 11 to afford Fmoc-protected compound 34.
- resultant amine 35 is reacted with ester 7 to produce Fmoc protected dye-labeled nucleotide 36.
- resultant amine 37 is reacted with dye NHS ester 14 to afford dye-labeled nucleotide 38.
- Example 6 A method for preparing a FRET-labeled nucleotide containing two anionic linkers is described in Example 6.
- the anionic linker between the nucleobase and first dye contains a phosphate diester moiety
- the anionic linker between the first and second dyes contains a sulfonic acid moiety.
- nucleotide amine 10 (Examples 1 and 2) is reacted with dye NHS ester 28 to form dye-labeled nucleotide 39, in which the dye and nucleotide are linked by a phosphate-containing linker.
- Example 7 illustrates how the dye-labeled nucleotide compound 40 from Example 6 can be used to form a conjugate ofthe invention by an alternative route, relative to the route described in Example 1.
- the main linker synthon between the first and second dyes is provided as part of compound 11, which contains a first dye (for attachment to the nucleobase) and an Fmoc-protected linker synthon that is attached to the first dye.
- the linker is provided as part of a compound (44) which contains a linker synthon attached to the second dye. This compound can be reacted with dye- labeled nucleotide 40 to obtain desired product 15.
- Example 7 illustrates how the order of connection of various synthons can be varied, if desired, to synthesize a particular compound ofthe invention.
- Examples 8A-8B describe methods for preparing two FRET-labeled nucleotides that are similar to the product of Example 1, except that the nucleobase is cytosine.
- the linkers are the same as for the product of Example 1.
- the linker between the nucleobase and first dye is longer than the conesponding linker in Example 8A, due to the inclusion of an ethoxy group inserted after the propargyl group.
- Examples 9, 10 and 11 describe methods for making additional FRET-labeled nucleobases (thymine) which contain selected anionic linkers between first and second dyes.
- the method in Example 9 produces a product 64 that has a sulfonate-containing anionic linker between the two dyes, and a charge-neutral linker between the first dye and nucleobase.
- Product 69 from Example 10 has a phosphate-containing anionic linker between the first and second dyes. This anionic linker is also longer than the linker of Example 9 (18 linker chain atoms versus 10 linker chain atoms).
- the method in Example 11 produces a product 77 similar to product 69, except that the nucleobase is 7- deazaguanosine, and the attached dye is different.
- Example 12A describes a method for preparing a dye-labeled conjugate 82 having an anionic linker that contains a sulfonate group, as illustrated by a sulfonated benzene moiety.
- dye-labeled conjugate 85 has a dianionic linker (net formal charge of -2) that contains both a sulfonate group and a phosphate group.
- dye-labeled conjugate 95 has an anionic linker containing a phosphodiester moiety within the linker chain.
- Example 18 provides a method of forming a conjugate of the form B-L-D having a linker that comprises a carboxyl anionic group, as illustrated with a carboxy benzene moiety as part of the linker.
- carboxylic acid groups can also be included in linkers in other ways, by preparing appropriate carboxylated linker synthons.
- Examples 14, 15 and 16 provide additional methods for preparing FRET-labeled conjugates wherein the nucleobase and first dye are linked by an anionic linker, and the donor and acceptor dyes are linked by a charge-neutral linker.
- the nucleobase in Examples 14 and 16 is 7-deazaadenine.
- the nucleobase in Example 15 is 7-deazaguanine.
- a phosphodiester moiety is linked to a 7-propargyl group on the nucleobase, and the remainder of the linker is provided as an ethylaminoacyl moiety linked to the pendent phenyl ring of a fluorescein dye.
- a phosphodiester moiety is linked to the nucleobase by a 7-propargylphenylpropynyl group, and the remainder of the linker is provided as an ethylaminoacyl moiety.
- a phosphonate monoester is linked to the nucleobase by a methylacylaminopropargyl group, and the remainder of the linker is provided as an ethylaminoacyl moiety.
- the foregoing examples illustrate a broad variety of dye-labeled nucleobase compounds in accordance with the invention, including four different types of nucleobases, linkers of different compositions and lengths, a number of different types of dyes, and various combinations thereof.
- conjugates of the form B-Ll- D1-L2-D2 are described wherein LI, L2 or both, . are anionic linkers of various types and lengths.
- conjugates of the form B-L-D are also provided (Examples 12A, 12B, and 13), and modifications should be immediately apparent from the FRET pair Examples in which LI is an anionic linker.
- the present invention also includes nucleosides and nucleotides containing conjugates in accordance with the invention. Particularly prefened nucleosides/tides of the present invention are shown below in the following formula:
- Wi is OH, H, F, Cl, NH 2 , N 3 , or OR, where R is C1-C6 alkyl (e.g., OCH 3 or OCH 2 CH ); W 2 is OH or a group capable of blocking polymerase-mediated template-directed primer extension (such as H, F, Cl, NH 2 , N 3 , or OR, where R is C1-C6 alkyl (e.g., OCH 3 or OCH 2 CH 3 )); W 3 is OH, or mono-, di- or triphosphate or a phosphate analog thereof; and LB (labeled base) represents a dye-labeled nucleobase conjugate of the invention.
- Wi is not OH.
- W 2 is not OH, so that the compound is not 3' extendable.
- Wi and W 2 are selected from H, F, and NH .
- W ⁇ is F and W 2 is H, or W] is H and W 2 is F, or Wj. and W 2 are each F, or Wi and W 2 are each H.
- W can be OH, monophosphate, diphosphate, or triphosphate.
- exemplary nucleobases include adenine, 7-deazaadenine, 7-deaza-8-azaadenine, cytosine, guanine, 7-deazaguanine, 7- deaza-8-azaguanine, thymine, uracil, and inosine.
- the present invention when W 3 is triphosphate, the present invention includes nucleotide triphosphates having the structure shown in the formula below:
- terminator nucleotides and others discussed above which lack a 3' OH group, find particular application as chain terminating agents in Sanger-type DNA sequencing methods utilizing fluorescent detection, and also in minisequencing.
- the invention includes deoxynucleotide triphosphates having the structure shown in the formula below:
- Labeled 2'-deoxynucleotides of this type find particular application as reagents for labeling polymerase extension products, e.g., in the polymerase chain reaction and nick-translation.
- the invention includes ribonucleotide triphosphates having the structure shown in the formula below: wherein LB is defined as above.
- Labeled nucleotides of this type find particular application as reagents for and in sequencing methods that utilize labile nucleotides having cleavable internucleotide linkages, as discussed for example in US Patent 5,939,292 (Gelfand et al.), Eckstein, Nucl Acids Res. 16:9947-9959 (1988), and Shaw, Nucl. Acids Res. 23 :4495 (1995).
- the invention also provides polynucleotides and mixtures of polynucleotides that contain one or more different nucleobase-dye conjugates of the type discussed above.
- Such polynucleotides are useful in a number of important contexts, such as DNA sequencing, ligation assays, the polymerase chain reaction (PCR), probe hybridization assays, and various other sequence detection or quantitation methods.
- Dye-containing polynucleotides may be synthesized enzymatically, e.g., using a DNA or RNA polymerase, nucleotidyl transferase, ligase, or other enzymes, e.g., Stryer, Biochemistry, Chapter 24, W.H. Freeman and Company (1981), or by chemical synthesis, e.g., by the phosphoramidite method, the phosphite-triester method, or the hke.
- Dye-labels of the invention may be introduced during enzymatic synthesis utilizing labeled nucleotide triphosphate monomers as described above, or during chemical synthesis using labeled non-nucleoside or nucleoside phosphoramidites, or may be introduced subsequent to synthesis.
- Exemplary methods for forming labeled polynucleotides can be found in Sambrook et al. Molecular Cloning: A Laboratory Manual, 2nd Ed, Cold Spring Harbor Laboratory Press, NY (1989), US Patents 6,008,379 (Benson et al.), and references cited therein.
- a labeled polynucleotide is made using enzymatic synthesis, the following procedure may be used.
- An oligonucleotide primer is annealed to a complementary sequence in a template DNA strand.
- a mixture of deoxynucleotide triphosphates (such as dGTP, dATP, dCTP, and dTTP) is added, where at least one ofthe deoxynucleotides contains a nucleobase- dye conjugate of the invention.
- a dye-labeled polynucleotide is formed by incorporation of a labeled deoxynucleotide during polymerase- mediated strand synthesis.
- the polymerase is a thermostable polymerase
- the reaction temperature is cycled between a denaturation temperature and an extension temperature, thereby exponentially synthesizing (amplifying) a labeled complement to the target sequence by PCR, e.g., PCR Protocols, Innis et al. eds. Academic Press (1990).
- Labeled polynucleotides may be chemically synthesized using any suitable method, such as the phosphoramidite method.
- the phosphoramidite method is a preferred method because of its efficient and rapid coupling and the stability of the starting materials.
- the synthesis is performed with a growing polynucleotide chain attached to a solid support, so that excess reagents, which are in the liquid phase, can be easily removed by filtration, thereby eliminating the need for purification steps between synthesis cycles.
- the nucleobase-dye conjugates of the present invention are suited for any method utilizing fluorescent detection, particularly methods requiring simultaneous detection of analytes which are not well separated by electrophoresis.
- the present invention is particularly well suited for detecting classes of polynucleotides that have been subjected to a biochemical separation procedure, such as electrophoresis.
- the invention provides a method of identifying one or more polynucleotide(s).
- the method utilizes one or more labeled different-sequence polynucleotides, which may have the same lengths or different lengths, wherein each different-sequence polynucleotide contains a unique nucleobase-dye conjugate.
- the one or more labeled different-sequence polynucleotides are separated by electrophoresis to separate different-sequence polynucleotides on the basis of size.
- Each different-sequence polynucleotide can then be identified on the basis of its electrophoretic mobility and fluorescence signal.
- the polynucleotide(s) may be formed by any appropriate method, with the proviso that each different polynucleotide is identifiable on the basis of a unique combination of electrophoretic mobility and fluorescence signal.
- two different polynucleotides may contain identical dye moieties but may exhibit different electrophoretic mobilities.
- two different polynucleotides can contain different dye moieties that produce distinct (spectrally resolvable) fluorescence signals but can exhibit the same electrophoretic mobilities.
- different polynucleotides can differ in both their fluorescence signals and mobilities.
- the method can be used in a multiplex format in which different labeled polynucleotides are formed by reaction with (i) a plurality of different target sequences and (ii) a plurality of different polynucleotides that are complementary to the target sequences.
- the different polynucleotide can be designed to undergo a change in structure after hybridization to their complementary target sequences in a polynucleotide sample, e.g., due to modification by enzyme action, thereby producing different labeled polynucleotides having unique combinations of mobility and fluorescence to allow identification.
- Such reactions can be performed simultaneously in a single reaction mixture or can be performed in separate reaction mixtures that can be combined prior to electrophoretic separation.
- Sanger-type sequencing involves the synthesis of a DNA strand by a DNA polymerase in vitro using a single-stranded or double-stranded DNA template whose sequence is to be determined or confirmed. Synthesis is initiated at a defined site based on where an oligonucleotide primer anneals to the template. The synthesis reaction is terminated by incorporation of a nucleotide analog that will not support continued DNA elongation.
- Exemplary chain-terminating nucleotide analogs include the 2',3'-dideoxynucleoside 5'- triphosphates (ddNTPs) which lack the 3'-OH group necessary for 5' to 3' DNA chain elongation.
- ddNTPs 2',3'-dideoxynucleoside 5'- triphosphates
- enzyme-catalyzed polymerization will be te ⁇ ninated in a fraction of the population of chains at each site where the ddNTP is inco ⁇ orated.
- labeled ddNTPs are used for each reaction, a desired sequence read can be obtained by detection of the fluorescence signals of the terminated chains during or after separation by high-resolution electrophoresis.
- dyes of the invention can be attached to either sequencing primers or terminator nucleotides.
- fragment analysis or “genetic analysis” methods, labeled polynucleotide fragments can be generated through template-directed enzymatic synthesis using labeled primers or nucleotides, e.g., by polynucleotide ligation or polymerase-directed primer extension.
- the resultant fragments are then subjected to a size-dependent separation process, e.g., electrophoresis or chromatography, and the separated fragments are detected, e.g., by laser-induced fluorescence.
- a size-dependent separation process e.g., electrophoresis or chromatography
- the separated fragments are detected, e.g., by laser-induced fluorescence.
- multiple classes of polynucleotides are separated simultaneously and the different classes are distinguished by spectrally resolvable labels.
- a fragment analysis method known as amplified fragment length polymorphisim detection (AmpFLP) is based on amplified fragment length polymorphisms, i.e., restriction fragment length polymorphisms that are amplified by PCR. These amplified fragments of varying size serve as linked markers for following mutant genes in family lineages. The closer the amplified fragment is to the mutant gene on the chromosome, the higher the linkage conelation. Because genes for many genetic disorders have not been identified, these linkage markers serve to help evaluate disease risk or paternity.
- the polynucleotides may be labeled by using a labeled polynucleotide PCR primer, or by utilizing labeled nucleotide triphosphates in the PCR.
- a labeled polynucleotide PCR primer or by utilizing labeled nucleotide triphosphates in the PCR.
- nick translation one or more unlabeled nucleotide subunits in a double-stranded DNA molecule are replaced with labeled subunits. Free 3'-hydroxyl groups are created within the unlabeled DNA by "nicks" caused by treatment with deoxyribonuclease I (DNAase I).
- the DNA polymerase I then catalyzes the addition of one or more labeled nucleotides to the 3'-hydroxyl ofthe nick.
- the 5' to 3'- exonuclease activity of this enzyme can remove one or more nucleotide subunits from the 5 1 - phosphoryl terminus ofthe nick.
- a new nucleotide with a free 3'-OH group is incorporated at the position of the excised nucleotide, and the nick is shifted along by one nucleotide unit in the 3' direction. This 3' shift will result in the sequential addition of new labeled nucleotides to the DNA with the removal of existing unlabeled nucleotides.
- the nick-translated polynucleotide is then analyzed using a separation process, e.g., electrophoresis.
- VNTRs are regions of double-stranded DNA that contain adjacent multiple copies of a particular sequence, with the number of repeating units being variable among different members of a population (e.g., of humans). Examples of VNTR loci are pYNZ22, pMCT118, and Apo B.
- a subset of VNTR methods are based on the detection of microsatellite repeats, or short tandem repeats (STRs), i.e., tandem repeats of DNA characterized by a short (2-4 bases) repeated sequence.
- STRs short tandem repeats
- oligonucleotide ligation assay two polynucleotides (probe pair) which are complementary to adjacent regions in a target sequence are hybridized to the target region of a polynucleotide, to create a nicked duplex structure in which the ends ofthe two polynucleotide abut each other.
- the two probes can be joined by ligation, e.g., by treatment with ligase.
- the ligated product is then detected, evidencing the presence ofthe target sequence.
- the ligation product acts as a template for a second pair of polynucletide probes which are complementary to the ligated product fromthe first pair.
- the target sequence is amplified exponentially, allowing very small amounts of target sequence to be detected and/or amplified.
- a fragment analysis method such as any of those discussed above can be performed in a multi-probe format, in which a sample is reacted with a plurality of different polynucleotide probes or probe sets which are each specific for a different target sequence, such as different alleles of a genetic locus and/or different loci.
- the probes are designed to have a unique combination of mobility and fluorescence signal, to permit specific detection ofthe individual probes or probe products that are generated in the assay as a result ofthe presence ofthe different target sequences.
- labeled polynucleotides are preferably separated by electrophoretic procedures.
- Methods for electrophoresis of nucleic acids are well known and are described, for example in Rickwood and Hames, Eds, Gel Electrophoresis of Nucleic Acids: A Practical Approach, IRL Press Limited, London (1981), Osterman, Methods of Protein and Nucleic Acid Research, Vol. 1 Springer- Verlag, Berlin (1984), Sambrook et al. (1989, supra), P.D. Grossman and J.C. Colburn, Capillary Electrophoresis: Theory and Practice, Academic Press, Inc., NY (1992), and U.S. Patents 5,374,527, 5,624,800 and/or 5,552,028.
- the electrophoretic matrix contains crosslinked or uncrosslinked polyacrylamide having a concentration (weight to volume) of between about 2-20 weight percent, and often about 4 to 8 percent.
- the electrophoresis matrix usually includes a denaturing agent such as urea, formamide, or the like.
- a denaturing agent such as urea, formamide, or the like.
- Detailed exemplary procedures for forming such matrices are given by Maniatis et al, "Fractionation of Low Molecular Weight DNA and RNA in Polyacrylamide Gels Containing 98% Formamide or 7 M Urea," in Methods in Enzymology, 65: 299-305 (1980), Sambrook et al. (1989, supra), and ABI PRISMTM 377 DNA Sequencer User's Manual, Rev.
- electrophoresis media are also commercially available from Applied Biosystems and other vendors, including non- crosslinked media, for use with automated instruments such as the Applied Biosystems "3700" and "3100” Instruments, by way of example.
- Optimal electrophoresis conditions e.g., polymer concentration, pH, temperature, voltage, concentration of denaturing agent, employed in a particular separation depends on many factors, including the size range ofthe nucleic acids to be separated, their base compositions, whether they are single stranded or double stranded, and the nature of the polynucleotides for which information is sought by electrophoresis. Accordingly application ofthe invention may require standard preliminary testing to optimize conditions for particular separations.
- the labeled polynucleotides can be detected or identified by recording fluorescence signals and migration times (or migration distances) of the separated polynucleotides, or by constructing a chart of relative fluorescent and order of migration of the polynucleotides (e.g., as an electropherogram).
- the labeled polynucleotides can be illuminated by standard means, e.g. a high intensity mercury vapor lamp, a laser, or the like.
- the labeled polynucleotides are illuminated by laser light generated by a He-Ne gas laser or a solid-state diode laser.
- the fluorescence signals can then be detected by a light-sensitive detector, e.g., a photomultiplier tube, a charged-coupled device, or the like.
- a light-sensitive detector e.g., a photomultiplier tube, a charged-coupled device, or the like.
- Exemplary electrophoresis detection systems are described elsewhere, e.g., U.S. Patent Nos. 5,543,026, 5,274,240, 4,879,012, 5,091,652 and 4,811,218.
- Figs. 19A-19B, 20A-20B, and 21A-21B show various results in support of the present invention. The results were obtained for sequencing fragments prepared by template-dependent primer extension in the presence of selected dye-labeled terminators following the methodology described in US Patent 6,096,875 (see Example 12, except that the primers were not labeled).
- Primer extension reactions were performed in the presence of a single type of terminator to generate a ladder of extension fragments.
- the two extension reactions in each study differed only in the linkers that were present between the nucleobase and the dye, or between a donor dye and acceptor dye.
- the linker in one reaction mixture (A) is non-anionic
- the linker in the other reaction mixture (B) is an exemplary anionic linker.
- Figs. 19A and 19B two primer extension reactions were performed using 7- deaza analogs of dideoxyguanosine-5 '-triphosphate (ddGTP).
- Both terminators contained only one dye, which is a dibenzoxanthene dye ofthe type described in US Patent 5,936,087 at Fig. 14, wherein Ri is CH 2 -j5-C 6 H 4 and R 2 is propyldiyl, and wherein the C4 and CIO of the benzo groups are sulfonated.
- the dye is linked by the 12-nitrogen atom of the dibenzoxanthene ring structure to C7 of the 7-deazaguanine ring.
- the structure of the L linker is B-C ⁇ CCH 2 OCH 2 CH 2 NHC(O)- ⁇ -C 6 H 4 CH 2 -D, wherein B represents C7 of the nucleobase and D represents N12 of the dye.
- the structure of the L linker is B-C ⁇ CCH 2 OCH 2 CH 2 NHC(O)CH 2 OP(O)(OH)OCH 2 CH 2 -NH- C(O)-j9-C6H4CH 2 -D, wherein B and D are as just described.
- FIG. 19A An arrow in Fig. 19A points to a middle peak flanked on each side by a left peak and a right peak.
- the spacing between the left and middle fragments appears to be about equal to the spacing between the middle and right fragments, suggesting that the target sequence contains three cytosine subunits (complementary to the ddG terminator) which are separated from each other by an equal number of intervening subunits.
- the 3 '-terminal subunits of the fragments conesponding to the left and middle peaks are known to be separated by three intervening subunits, whereas the 3 '-terminal subunits ofthe fragments conesponding to the middle and right peaks are separated by only one intervening subunit.
- the middle peak is four subunits longer than the left peak, and the right peak is only two subunits longer than the middle peak.
- the middle peak could co-migrate with a longer or shorter fragment containing a different terminator, thereby obscuring the correct order of the fragments and rendering indeterminate the sequence information.
- the profile in Fig. 19B which was obtained using a dye-labeled nucleobase in accordance with the invention, has the expected spacing between the three peaks.
- the separation between the left and middle peaks is twice the separation between the middle and right peaks, consistent with length differences of four and two subunits, respectively, between the left, middle, and right peaks.
- this profile would allow a user to more easily determine the conect target sequence.
- Figs. 20A and 20B show electrophoretic profiles obtained using two different 7- deaza analogs of dideoxyadenosine-5 '-triphosphate (ddATP).
- both terminators contained a donor/acceptor dye pair in which Dl is a 6-carboxyfluorescein containing a 5'-amino methyl group, and D2 is the same as the 5-carboxy-4,7- dichlororhodamine dye used in Example 1 herein.
- Dl is linked via the 4'amino methyl group to C5 of the pendent phenyl ring of D2 using the L2 linker from Example 1.
- B and Dl were linked by the LI linker from Example 4 (-C ⁇ CCH 2 NHC(O)-).
- B and Dl were linked by an LI linker of the form: B-C ⁇ CCH 2 NHC(O)-p-C 6 H 4 (SO 3 )CH 2 NHC(O)-Dl, wherein the sulfonate group on the benzene ring is ortho to the aminomethyl group.
- the profile in the left-hand window of Fig. 20A contains a single peak that is separated from a quartet of four peaks on the right. From the approximately equal spacing between adjacent peaks in the quartet, a user would probably conclude that the target sequence contains four consecutive thymidine subunits. However, such a conclusion would be enoneous, since the target sequence actually contains an adenosine subunit between the third and fourth thymidine subunits.
- a profile having a significantly improved profile is shown in the left-hand window of Fig. 20B. In particular, the third and fourth peaks in the quartet are separated by a distance consistent with a length difference of two subunits for those peaks.
- the right-hand window of Fig. 20A shows a set of closely eluting peaks which are numbered 1, 3, 5, 6, 8, and 10.
- the conect terminator sequence reading is 5'-ACACAACATA-3' (conesponding to a template sequence of 3'-TGTGTTGTAT-5').
- peaks 5 and 6 in the right-hand window of Fig. 20A are separated from each other by more than one peak interval, so that a user might conclude that the two peaks are separated by an intervening fragment conesponding to the presence of an intervening subunit in the target sequence.
- One “peak interval” refers to the average spacing between adjacent peaks differing in length by one nucleotide, for a selected region of an electropherogram.
- Each peak corresponds to a unique-sequence fragment of DNA.
- peaks 5 and 6 are separated by about one peak interval, as expected for fragments that differ in length by one nucleotide subunit.
- the improvement in spacing between peaks 1, 3, 5, 6, 8 and 10 allows more accurate determination ofthe target sequence.
- Figs. 21A and 21B Yet another example of the advantages of the invention is illustrated in Figs. 21A and 21B.
- extension reactions were performed using 7-deaza analogs of ddATP.
- Both terminators contained a fluorescein dye (compound 33 from US Patent 6,008,379) which is linked via C5 of the pendent phenyl ring to C7 of the 7-deazaadenine ring.
- the structure of the L linker is B-C ⁇ C-p-C 6 H4- C ⁇ CCH 2 OCH 2 CH 2 NHC(O)-D, wherein B represents C7 of the nucleobase and D represents C5 of the pendent phenyl ring of the dye.
- the structure of the L linker is B-C ⁇ C- ⁇ -C 6 H 4 -C ⁇ CCH 2 OCH 2 CH 2 NHC(O)-
- Fig. 21A shows a profile containing four peaks consisting of a singlet on the left, a singlet in the middle, and a doublet on the right. From the known target sequence, the singlets should be separated from each other by four peak intervals (due to the presence of three intervening non-T subunits in the target sequence), the middle singlet and left-hand peak in the doublet should also be separated by four peak intervals, and the two peaks in the doublet should be separated from each other by one peak interval.
- the profile in Fig. 21A is problematic because the middle singlet is separated from the left-hand member of the doublet by approximately 3.5 peak intervals, h the profile shown in Fig.
- the spacing is more uniform, such that the middle singlet and left-hand peak in the doublet are separated by four peak intervals.
- the target sequence can be determined more easily using the dye-labeled terminator of Fig. 2 IB in accordance with the invention.
- the present invention provides conjugate compounds in which a dye and nucleobase are linked by an anionic linker, or, in the case of energy transfer dyes, one or more linkers located between a dye and a nucleobase and/or between energy transfer dyes are anionic linkers.
- linkers can be used in a variety of different forms and may include any of a variety of different anionic groups, such that base-pairing characteristics of the nucleobase and fluorescent properties of the dye are retained.
- Compounds of the invention are useful in nucleoside and nucleotides that can be incorporated into polynucleotides for detection.
- polynucleotides containing dye-labeled conjugates of the invention show reduced sequence-dependent variations in electrophoretic mobility.
- the invention provides electrophoretic separation patterns having more even spacing between nearby polynucleotide bands, as well as reduced band-compression, resulting in a more consistent and uniform relationship between polynucleotide length and electrophoretic mobility.
- nucleoside triphosphates that contain nucleobase- dye conjugates of the invention are good substrates for polymerase enzymes which can be used to incorporate such nucleotides into polynucleotides to form labeled polynucleotides. This is advantageous in terminator-based sequencing methods. When compounds of the invention are incorporated at the 3' ends of sequencing fragments, artifacts in electrophoretic mobility are reduced, so that accuracy of base-calling can be improved.
- the kit comprises at least one labeled nucleoside triphosphate comprising a conjugate described herein.
- the kit may also include one or more of the following components: a 3 '-extendable primer, a polymerase enzyme, one or more 3' extendable nucleotides which are not labeled with conjugate, and/or a buffering agent.
- the kit includes at least one labeled nucleoside triphosphate that is nonextendable.
- the kit comprises four different labeled nucleoside triphosphates which are complementary to A, C, T and G, and each of which contains a distinct conjugate as described herein.
- the labeled nucleoside triphosphates are nonextendable. In another embodiment, the labeled nucleoside triphosphates are extendable ribonucleoside triphosphates. In another embodiment, the kit comprises at least one labeled, nonextendable nucleoside triphosphate comprising a conjugate described herein, and one or more of the following components: a 3'-extendable primer, a polymerase enzyme, and/or a buffering agent.
- Example 1 Synthesis of Dye-Nucleotide Conjugate 15 Methyl glycolate 2 (4.5 eq.) was added to Amino-LinkTM 1 (1 eq.) (Connell, C, et al, BioTechniques 5:342-348 (1987); US Patent 4,757,151), followed by 4-N,N-dimethyl aminopyridine (DMAP) (0.1 eq.). The mixture was stined at ambient temperature for 1 hour. After the reaction was complete (TLC analysis), the solution was cooled with ice- bath and then treated with a solution of 3-chloroperoxybenzoic acid (4 eq.) in methylene chloride. The ice-bath was removed.
- Amino-LinkTM 1 (1 eq.)
- DMAP 4-N,N-dimethyl aminopyridine
- Nucleoside triphosphate 8 (7-(3-amino-l-propynyl)-2',3'-dideoxy-7- deazaadenosine-5' -triphosphate ⁇ see US Patents 5,047,519 and 5,151,507 by Hobbs et al. for synthesis) in 100 mM TEA-bicarbonate solution (pH 7.0) was evaporated to dryness. The dried residue was suspended in a solution of 250 mM bicarbonate (pH 9.0). A solution of compound 7 in DMSO was added. After 1 hour, the reaction mixture was purified by HPLC (AX-300 anion exchange). The product fractions were collected, concentrated to dryness, and purified by RP HPLC (C-18 reverse phase) to afford compound 9.
- HPLC AX-300 anion exchange
- Ammonium hydroxide solution (28-30%) was added to dried compound 9. The solution was heated to 55°C for 20 minutes. Concentration under vacuum gave crude compound 10 which was purified by HPLC (C-18 reverse phase).
- NHS-ester dye intermediate 11 was prepared by reacting the fluorenylmethoxy- carbonyloxy ester of N-hydroxysuccinimide with the HCl salt of ?-aminomethylbenzoic acid (both commercially available) in the presence of base to form the expected N-Fmoc derivative. This product was then reacted with N-hydroxysuccinimide in the presence of DCC to form the NHS ester of the benzoic acid carboxyl group. This NHS ester was then reacted with 4'-aminomefhyl-6-carboxyfluorescein (M.T. Shipchandler et al. Anal Biochem. 162:89-101 (1987)) to form the expected product.
- M.T. Shipchandler et al. Anal Biochem. 162:89-101 (1987) 4'-aminomefhyl-6-carboxyfluorescein
- Nucleoside 20 (7-iodo-7-deazaadenosine, 1 eq.) was reacted with linker synthon 19 (2 eq.) in the presence of cuprous iodine (0.4 eq.), tetrakis(triphenylphosphine)palladium (0.4 eq.), and triethylamine (8 eq.) in N,N-dimethylformamide for 4 hours. The reaction was concentrated and purified by flash column chromatography to afford nucleoside 21.
- Phosphorous oxychloride (6 eq.) was added to nucleoside 21 (1 eq.) in trimethylphosphate at 0°C to form the conesponding dichloromonophosphate 22.
- the reaction mixture was stined at 0°C for 2 hours after which it was transfened via cannula to another flask containing tributylammonium pyrophosphate (12 eq.) and tributylamine (22 eq.) in the presence of DMF. After another 30 minutes at 0°C, the solution was quenched with TEAB buffer (IM). The solution was then stirred overnight at ambient temperature. Purification was carried out by HPLC (C-18 reverse phase) to afford nucleoside triphosphate 23.
- nucleotide 10 can be used in the synthesis of compound 15 as described in Example 1.
- Example 3 General Coupling Reactions For the Examples below, the following general conditions were used. For reactions involving the coupling of an amino group to an N-hydroxysuccinimide-activated carboxyl group (NHS ester), the compound containing the amino group was suspended in 100 mM TEA-bicarbonate (pH-7.0) and evaporated to dryness.
- Fmoc groups were removed by heating at 55 °C for 20 minutes in the presence of 28-30% ammonium hydroxide.
- N-hydroxysuccinimide and N,N-dimethylformamide were added to a slurry solution of compound 26 (1 eq.) in methylene chloride.
- the solution was cooled to 0°C, followed by addition of a solution of dicyclohexylcarbodiimide (DCC, 2 eq.) in methylene chloride.
- DCC dicyclohexylcarbodiimide
- the ice-bath was removed and stirring was continued for 2 hours.
- the mixture was diluted with ethyl acetate, and the organic portion was washed with aqueous solution of HCl (5%).
- Purified NHS ester 27 was obtained by flash column chromatography.
- Nucleoside triphosphate 8 (Example 1) was reacted with dye-NHS ester 28 (4'-N- trifluoroacetylaminomethyl-6-carboxyfluorescein according to procedures generally described in Example 3 to form the expected dye-labeled nucleotide 29. Removal of the trifluoroacetyl (TFA) protecting group (Example 3) from conjugate 29 afforded amine compound 30. Reaction of compound 30 with NHS ester 27 afforded the expected Fmoc- protected compound 31.
- dye-NHS ester 28 (4'-N- trifluoroacetylaminomethyl-6-carboxyfluorescein according to procedures generally described in Example 3 to form the expected dye-labeled nucleotide 29. Removal of the trifluoroacetyl (TFA) protecting group (Example 3) from conjugate 29 afforded amine compound 30. Reaction of compound 30 with NHS ester 27 afforded the expected Fmoc- protected compound 31.
- nucleotide-dye compound 33 which contains a sulfonate substituent in the linker chain between the two dyes.
- Example 6 Synthesis of Dve-Nucleotide Conjugate 43
- Nucleotide 10 (Example 1) was combined with TFA-protected fluorescein NHS ester 28 to afford the expected dye-nucleotide conjugate 39.
- the resultant deprotected product 40 was reacted with NHS ester 27 to afford Fmoc-protected conjugate 41.
- nucleotide-dye conjugate 43 having a phosphate diester moiety within the chain of linker atoms between the inner dye and the nucleobase, and a sulfonate substituent in the linker between the two dyes.
- Example 8 Synthesis of Dve-Nucleotide Conjugates 51 and 57 8 A.
- 5-(3-amino-l-propynyl)-2',3' r dideoxycytidine-5' -triphosphate 45 was reacted with NHS ester 7 (Example 1) to afford Fmoc-protected intermediate 46.
- Removal of the Fmoc group afforded amine 47 which was then reacted with NHS ester 11 (Example 1) to afford conjugate 48.
- Removal of the Fmoc protecting group afforded amine 49 which was then reacted with rhodamine NHS ester 50 (e.g., see US Patent 5,847,162, for synthesis) to afford conjugate 51.
- Example 8B The protocol in Example 8 A was carried out using 5-(3-aminoethoxy-l- propynyl)-2',3'-dideoxycytidine-5'-triphosphate 52 (e.g., see US Patent 5,821,356 for synthesis) instead of nucleotide triphosphate 45, to afford conjugate 57.
- 5-(3-aminoethoxy-l-propynyl)-2',3'-dideoxythymidine-5'-triphosphate 58 (e.g., see US Patent 5,821,356 for synthesis) instead of nucleotide 8, dye-NHS ester 28 (supra), linker NHS ester 27 (supra), and dye-NHS ester 63 (e.g., prepared following methods described in US Patent 6,080,852) instead of compound 14.
- Example 10 Synthesis of Dve-Nucleotide Conjugate 69 Using procedures described in Example 5, conjugate 69 was prepared from 5-(3- arninoethoxy-l-propynyl)-2',3'-dideoxythymidine-5'-triphosphate 58 (Example 9) instead of nucleotide 8, dye NHS ester 11 (supra), phosphate linker synthon 7 (supra), and dye NHS ester 63 (Example 9) instead of compound 14.
- conjugate 77 was prepared from 7-(3- aminoethoxy-l-propynyl)-2',3'-dideoxy-7-deazaguanosine-5'-triphosphate 70 instead of nucleotide 8, dye NHS ester 71 (prepared in the same way as compound 11 supra, using the
- Dye-nucleotide conjugate 85 was prepared by coupling deprotected amine 80
- Example 12 A to phosphate-containing linker synthon 7 (supra) to afford Fmoc-protected product 83.
- resultant amine 84 was coupled to NHS- activated dye 81 (Example 12A) to afford dye-nucleotide conjugate 85 having a linking group containing both a sulfonate group and a phosphate group.
- NHS ester 91 was obtained by treating compound 90 with DCC (1.3 eq.) and N-hydroxysuccinimide (3 eq.). NHS ester 91 was added to nucleotide 78 (Example 12 A) to form Fmoc-protected compound 92. After removal ofthe Fmoc group, resultant amine compound 93 was coupled to dye 81 (Example 12 A) to afford dye-nucleotide conjugate 95 containing a phosphodiester within the linker chain.
- Phosphodiester 98 (1.5 eq.) was reacted with 7-iodo-7-deazaadenosine 20 (1 eq.) in the presence of Cul (0.4 eq.), Pd[PPh 3 ] (0.4 eq.), and triethylamine (8 eq.) in DMF to afford nucleoside product 99.
- Phosphorous oxychloride (6 eq.) was reacted with nucleoside 99 (1 eq.) to form dichlorophosphate intermediate 100.
- This intermediate was treated with tributylammonium pyrophosphate (12 eq.) and tributylamine (22 eq.), followed by hydrolysis with TEAB buffer (1 M), to form nucleotide 5' triphosphate 101. Removal of the TFA group was achieved by ammonium hydroxide to afford nucleotide amine 102.
- Dye NHS ester 11 (Example 1) was added to nucleotide amine 102 in NaHCO 3 buffer to afford dye-nucleotide 104. After the Fmoc group was removed, the resultant amine compound 105 was coupled to dye NHS ester 14 (Example 1) to afford dye- nucleotide conjugate 106.
- Triethylsilylacetylene 108 (3 eq.) was coupled to 4-iodophenol 107 (1 eq.) in the presence of Cul (0.05 eq.), Pd[PPh 3 ] 4 (0.05 eq.), and triethylamine (2 eq.) in DMF. The mixture was stirred at ambient temperature for 5 hours after which it was concentrated under vacuum to afford a crude black oil. The oil was purified by flash column chromatography to afford pure p-(triethylsilyl)ethynyl phenol 109.
- Propargyl alcohol 110 (1.1 eq.) was coupled to compound 111 (1 eq.) in the presence of Cul (0.1 eq.), Pd[PPh 3 ] 4 (0.05 eq.), and triethylamine (2 eq.) in DMF. The mixture was stirred at 60°C for 7 hours and then concentrated under vacuum. Purification by flash column chromatography gave alcohol 112. Alcohol 112 (1 eq.), Amino-LinkTM 1 (1 eq.), and DMAP (0.1 eq.) were reacted together using procedures described above, followed by oxidation with mCPBA (1.2 eq.) to produce phosphotriester 113.
- nucleoside 116 (7-iodo-3'-fluoro-2',3'- dideoxy-7-deazaguanosine, 1 eq.) (e.g., see Hobbs et al, supra, for synthesis) in the presence of Cul (0.4 eq.), Pd[PPh 3 ] 4 (0.4 eq.), and triethylamine (10 eq.) in DMF to afford nucleoside 117.
- Phosphorous oxychloride (6 eq.) was reacted with nucleoside 117 (1 eq.) to form intermediate 118 which was treated with tributylammonium pyrophosphate (12 eq.) and tributylamine (22 eq.), followed by hydrolysis with TEAB buffer (1 M) to form nucleotide 119. Removal ofthe TFA group was achieved using ammonium hydroxide to afford amine 120.
- Dye 71 was added to nucleotide amine 120 in NaHCO 3 buffer to afford dye- labeled nucleotide 122 (in these examples, there is no compound 121). After the Fmoc group was removed, the resultant amine compound 123 was coupled with dye 76 (Example 11) to afford dye-nucleotide conjugate 124.
- Lithiated tert-butyl acetate 125 prepared from tert-butyl acetate and lithio N,N- diisopropylamine (prepared according to M.W. Rafhke et al, J. Amer. Chem. Soc. 95:3050 (1973)) in hexane, is added dropwise to a hexane solution of 2-cyanoethyl diisopropylchlorophosphoramidite 126 (Aldrich Chemical Company) under an inert atmosphere. The reaction mixture is washed free from salts with water.
- Phosphonite 129 is dissolved in dry dichloromethane. To the solution is added 1.5 equivalents of tert-butyl hydroperoxide (TBHP) in dichloromethane. After complete reaction, the excess TBHP is removed from the reaction mixture by washing with water. The resultant organic layer is dried over anhydrous sodium sulfate, filtered, reduced in volume, and the phosphonate diester product 130 is isolated by column chromatography on silica gel by elution with hexane and dichloromethane.
- TBHP tert-butyl hydroperoxide
- Phosphonate diester 130 is dissolved in dichloromethane, and 2 equivalents of tri- fluoroacetic acid (TFA) are added. After the reaction is complete, the excess TFA is removed by washing with water. The resultant organic layer is dried over anhydrous sodium sulfate, filtered, reduced in volume, and the phosphonate diester carboxylic acid 131 is isolated by column chromatography on silica gel by elution with methanol and acetic acid in dichloromethane.
- TFA tri- fluoroacetic acid
- Phosphonate diester 131 is dissolved in ethyl acetate. To the solution is added N- hydroxysuccinimide (NHS, 2 eq.) and dicyclohexylcarbodiimide (DCC, 1.2 eq.). After the reaction is complete, dicyclohexylurea is removed by filtration, and excess NHS is removed by washing with water. The resultant organic layer is dried over anhydrous sodium sulfate, filtered, reduced in volume, and the phosphonate NHS ester 132 is isolated by column chromatography on silica gel by elution with hexane and dichloromethane.
- NHS N- hydroxysuccinimide
- DCC dicyclohexylcarbodiimide
- Phosphonate NHS ester 132 is added to nucleotide 8 (Example 1) in NaHCO 3 buffer to afford nucleotide 133.
- the resultant nucleotide amine 134 is coupled to dye-NHS ester 11 (Example 1) to afford the expected dye-labeled nucleotide 135.
- the Fmoc group is removed, and the amine product 136 is coupled with dye-NHS ester 14 (Example 1) to afford dye-nucleotide conjugate 137.
- Bicyclic amine t-Boc ester 141 (12.8 gm, 47 mmole, US Patent No. 5,688,808), 1- bromo-3-chloropropane (29.3 gm, 187 mmole), sodium iodide (56.4 gm, 376 mmole) and sodium bicarbonate (7.9 gm, 94 mmole) were refluxed together in 150 ml CH3CN for 18 hours. The mixture was cooled to room temperature, filtered, and evaporated.
- the filter cake was washed with 300 ml hexane which was combined with the filtrate and washed with 2 x 50 ml water and 50 ml saturated NaCI, dried over MgSO 4 , filtered, and concentrated under vacuum.
- the product was purified by chromatography on silica gel, eluting with hexane/ethyl acetate : 20/1, to give tricyclic amine pivalate ester 142 (pale yellow oil, 9.5 gm, 30 mmole, 64% yield).
- the ester group of 142 was hydrolyzed in a solution of lithium hydroxide monohydrate (2.6 gm, 60 mmole) in 15 ml water and 120 ml methanol.
- 4-Cyanoisophthalic acid dimethyl ester 203 (1.70g, 7.76mmol) was dissolved in methanol (lOOmL) and then treated with an aqueous solution of lithium hydroxide (2.0g, 46.5mmol) in 50mL of water. The basic solution was stirred at ambient temperature for 1.5 hour. It was then poured into a 10% HCl solution. The solution was extracted with ethyl acetate and the combined extracts were dried over Na 2 SO 4 .
- the following can be used as a general procedure to produce dye conjugates from compound 209 and an activated ester, such as an NHS ester of a dye (refened to as "NHS dye” in Fig. 22B).
- an activated ester such as an NHS ester of a dye (refened to as "NHS dye” in Fig. 22B).
- Compound 209 (1 equiv) is suspended in a minimum amount of a solution of 250 mM bicarbonate (pH 9.0), and a solution of dye NHS ester 210 in DMSO (3 equiv, 1 mg of dye NHS ester per 12 ⁇ L of DMSO) is then added.
- the reaction mixture is placed in the dark at ambient temperature for 1 hour.
- the product can be purified by anion exchange HPLC (AX-300) and then C-18 reverse phase HPLC to give pure dye-labeled nucleotide 211.
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP01981488A EP1317464B1 (en) | 2000-10-11 | 2001-10-11 | Fluorescent nucleobase conjugates having anionic linkers |
AU1312502A AU1312502A (en) | 2000-10-11 | 2001-10-11 | Fluorescent nucleobase conjugates having anionic linkers |
AU2002213125A AU2002213125B2 (en) | 2000-10-11 | 2001-10-11 | Fluorescent nucleobase conjugates having anionic linkers |
JP2002534329A JP4741170B2 (en) | 2000-10-11 | 2001-10-11 | Fluorescent nucleobase conjugates having an anionic linker |
AT01981488T ATE431355T1 (en) | 2000-10-11 | 2001-10-11 | FLUORESCENT NUCLEOBASECONJUGATES WITH ANIONIC LINKERS |
DE60138714T DE60138714D1 (en) | 2000-10-11 | 2001-10-11 | FLUORESCENT NUCLEOBASE CONJUGATES WITH ANIONIC LEFT |
CA002425663A CA2425663C (en) | 2000-10-11 | 2001-10-11 | Fluorescent nucleobase conjugates having anionic linkers |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US23966000P | 2000-10-11 | 2000-10-11 | |
US60/239,660 | 2000-10-11 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002030944A2 true WO2002030944A2 (en) | 2002-04-18 |
WO2002030944A3 WO2002030944A3 (en) | 2003-01-16 |
Family
ID=22903159
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/031822 WO2002030944A2 (en) | 2000-10-11 | 2001-10-11 | Fluorescent nucleobase conjugates having anionic linkers |
Country Status (8)
Country | Link |
---|---|
US (4) | US6811979B2 (en) |
EP (1) | EP1317464B1 (en) |
JP (1) | JP4741170B2 (en) |
AT (1) | ATE431355T1 (en) |
AU (2) | AU2002213125B2 (en) |
CA (1) | CA2425663C (en) |
DE (1) | DE60138714D1 (en) |
WO (1) | WO2002030944A2 (en) |
Cited By (51)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7262013B2 (en) | 2003-08-29 | 2007-08-28 | Applera Corporation | Bisulfite method |
JP2008501679A (en) * | 2004-06-02 | 2008-01-24 | エーエスエム サイエンティフィック, インコーポレイテッド | 2'-nitrobenzyl modified ribonucleotide |
WO2008039997A2 (en) * | 2006-09-28 | 2008-04-03 | Applera Corporation | Nucleobase conjugates with cationic backbone linkers |
US7368239B2 (en) | 2003-08-29 | 2008-05-06 | Applera Corporation | Method and materials for polyamine catalyzed bisulfite conversion of cytosine to uracil |
US7371526B2 (en) | 2003-08-29 | 2008-05-13 | Applera Corporation | Method and materials for bisulfite conversion of cytosine to uracil |
US7534873B2 (en) | 2003-08-29 | 2009-05-19 | Applied Biosystems, Llc | Method and materials for quaternary amine catalyzed bisulfite conversion of cytosine to uracil |
US7585868B2 (en) | 2006-04-04 | 2009-09-08 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists |
US7658288B2 (en) | 2004-11-08 | 2010-02-09 | Applied Biosystems, Llc | Bisulfite conversion reagent |
EP2179996A1 (en) * | 2000-11-28 | 2010-04-28 | Applera Corporation | Sulfonated diarylrhodamine dyes |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US8569323B2 (en) | 2009-07-15 | 2013-10-29 | Intellikine, Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8785454B2 (en) | 2009-05-07 | 2014-07-22 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
WO2015175873A1 (en) | 2014-05-16 | 2015-11-19 | Life Technologies Corporation | Cell tracking reagents and their methods of use |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9939447B2 (en) | 2001-05-21 | 2018-04-10 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
WO2020132487A1 (en) | 2018-12-20 | 2020-06-25 | Life Technologies Corporation | Modified rhodamine dye and use thereof in biological assays |
WO2020132607A1 (en) | 2018-12-20 | 2020-06-25 | Life Technologies Corporation | Asymmetric rhodamine dye and use thereof in biological assays |
CN111410624A (en) * | 2020-01-09 | 2020-07-14 | 江西科技师范大学 | Asymmetric naphthalene-pyrrole hybrid diarylethene compound and application thereof |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
WO2021004379A1 (en) * | 2019-07-05 | 2021-01-14 | 南京金斯瑞生物科技有限公司 | Fluorescently labeled nucleic acid and synthesis method therefor |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2022020723A1 (en) * | 2020-07-23 | 2022-01-27 | Life Technologies Corporation | Energy transfer dye conjugates for use in biological assays |
EP4089098A1 (en) * | 2021-05-10 | 2022-11-16 | Miltenyi Biotec B.V. & Co. KG | Fret dye labeled reversible nucleotide terminators and their use in sequencing of dna |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE431355T1 (en) * | 2000-10-11 | 2009-05-15 | Applera Corp | FLUORESCENT NUCLEOBASECONJUGATES WITH ANIONIC LINKERS |
US6887690B2 (en) * | 2001-06-22 | 2005-05-03 | Pe Corporation | Dye-labeled ribonucleotide triphosphates |
EP1389638A1 (en) * | 2002-08-06 | 2004-02-18 | Roche Diagnostics GmbH | Improved fluorescent resonance energy transfer probes |
US7429596B2 (en) * | 2003-06-20 | 2008-09-30 | The Regents Of The University Of California | 1H-pyrrolo [2,3-D] pyrimidine derivatives and methods of use thereof |
JP5183063B2 (en) * | 2003-07-05 | 2013-04-17 | ザ ジョンズ ホプキンス ユニバーシティ | Methods and compositions for detection and enumeration of genetic variations |
WO2005063787A2 (en) * | 2003-12-23 | 2005-07-14 | Applera Corporation | Propargyl substituted nucleoside compounds and methods |
CA2472806A1 (en) | 2004-05-18 | 2005-11-18 | Petro-Canada | Compositions and methods for treating turf insect pests and diseases such as fungal infestations |
CA2575808A1 (en) * | 2004-08-02 | 2006-02-16 | Osi Pharmaceuticals, Inc. | Aryl-amino substituted pyrrolopyrimidine multi-kinase inhibiting compounds |
WO2006020947A2 (en) | 2004-08-13 | 2006-02-23 | Epoch Biosciences, Inc. | Phosphonate fluorescent dyes and conjugates |
US7767834B2 (en) * | 2004-08-13 | 2010-08-03 | Elitech Holding B.V. | Phosphonylated fluorescent dyes and conjugates |
US20090246762A1 (en) * | 2008-03-31 | 2009-10-01 | Applera Corporation, Applied Biosystems Group | Nucleic acid terminators incorporating a cationic moiety and methods for their use |
CN102124018A (en) * | 2008-04-29 | 2011-07-13 | 生命科技公司 | Unnatural polymerase substrates that can sustain enzymatic synthesis of double stranded nucleic acids from a nucleic acid template and methods of use |
KR20110025225A (en) | 2008-06-26 | 2011-03-09 | 선코 에너지 인코포레이티드 | Improved turfgrass fungicide formulation with pigment |
JP5569768B2 (en) * | 2008-12-02 | 2014-08-13 | 国立大学法人九州大学 | Nucleoside triphosphate derivative, nucleic acid probe, multi-labeled nucleic acid probe, and method for detecting target nucleic acid |
WO2011050938A1 (en) | 2009-10-26 | 2011-05-05 | Genovoxx Gmbh | Conjugates of nucleotides and method for the application thereof |
WO2012027623A2 (en) * | 2010-08-25 | 2012-03-01 | Pacific Biosciences Of California, Inc. | Cyanine dyes |
NZ609203A (en) | 2010-09-09 | 2014-10-31 | Suncor Energy Inc | Synergistic paraffinic oil and boscalid fungicides |
TWI434895B (en) | 2012-03-28 | 2014-04-21 | Ind Tech Res Inst | Dyes and photoelectric conversion devices containing the same |
US9605309B2 (en) | 2012-11-09 | 2017-03-28 | Genia Technologies, Inc. | Nucleic acid sequencing using tags |
US10550190B2 (en) | 2014-04-04 | 2020-02-04 | Merck Sharp & Dohme Corp. | Phosphate based linkers for intracellular delivery of drug conjugates |
EP3268050B1 (en) | 2015-03-09 | 2021-07-14 | The Trustees of Columbia University in the City of New York | Pore-forming protein conjugate compositions and methods |
WO2016154215A1 (en) * | 2015-03-23 | 2016-09-29 | The Trustees Of Columbia University In The City Of New York | Polymer tagged nucleotides for single molecule electronic snp assay |
EP3359191A4 (en) | 2015-10-05 | 2019-05-29 | Merck Sharp & Dohme Corp. | Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors |
WO2017062271A2 (en) | 2015-10-06 | 2017-04-13 | Merck Sharp & Dohme Corp. | Antibody drug conjugate for anti-inflammatory applications |
US10869929B2 (en) | 2016-01-29 | 2020-12-22 | Merck Sharp & Dohme Corp. | Phosphonate linkers and their use to facilitate cellular retention of compounds |
GB201711219D0 (en) | 2017-07-12 | 2017-08-23 | Illumina Cambridge Ltd | Short pendant arm linkers for nucleotides in sequencing applications |
JP7167531B2 (en) * | 2018-08-03 | 2022-11-09 | 株式会社島津製作所 | Electrophoresis separation data analysis device, electrophoresis separation data analysis method, and computer program for causing a computer to execute the analysis method |
CA3130693A1 (en) | 2019-02-19 | 2020-08-27 | Ultima Genomics, Inc. | Linkers and methods for optical detection and sequencing |
US11193891B2 (en) | 2019-12-20 | 2021-12-07 | Robert Bosch Gmbh | Receptors and spacers for a fluorescence-based lead ion chemosensor |
US11807851B1 (en) | 2020-02-18 | 2023-11-07 | Ultima Genomics, Inc. | Modified polynucleotides and uses thereof |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5986086A (en) * | 1997-06-20 | 1999-11-16 | Amersham Pharmacia Biotech Inc. | Non-sulfonated cyanine dyes for labeling nucleosides and nucleotides |
WO2001019841A1 (en) * | 1999-09-17 | 2001-03-22 | Amersham Pharmacia Biotech, Inc. | Charge-modified nucleic acid terminators |
Family Cites Families (65)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4481136A (en) * | 1979-09-07 | 1984-11-06 | Syva Company | Alkyl substituted fluorescent compounds and conjugates |
US4458066A (en) * | 1980-02-29 | 1984-07-03 | University Patents, Inc. | Process for preparing polynucleotides |
US4439356A (en) * | 1981-03-03 | 1984-03-27 | Syva Company | Unsymmetrical fluorescein derivatives |
US4415732A (en) * | 1981-03-27 | 1983-11-15 | University Patents, Inc. | Phosphoramidite compounds and processes |
US5242794A (en) * | 1984-12-13 | 1993-09-07 | Applied Biosystems, Inc. | Detection of specific sequences in nucleic acids |
US4757151A (en) * | 1985-11-14 | 1988-07-12 | Warner-Lambert Company | 2-substituted-[2-substituted-amino]-N-arylalkyl-3-[indol-3-yl] |
US4811218A (en) * | 1986-06-02 | 1989-03-07 | Applied Biosystems, Inc. | Real time scanning electrophoresis apparatus for DNA sequencing |
US5047519A (en) | 1986-07-02 | 1991-09-10 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
CA1340806C (en) * | 1986-07-02 | 1999-11-02 | James Merrill Prober | Method, system and reagents for dna sequencing |
US5151507A (en) * | 1986-07-02 | 1992-09-29 | E. I. Du Pont De Nemours And Company | Alkynylamino-nucleotides |
US4795699A (en) * | 1987-01-14 | 1989-01-03 | President And Fellows Of Harvard College | T7 DNA polymerase |
JPS641949A (en) * | 1987-06-24 | 1989-01-06 | Hitachi Ltd | Regeneration of electrophoretic gel |
US5231191A (en) * | 1987-12-24 | 1993-07-27 | Applied Biosystems, Inc. | Rhodamine phosphoramidite compounds |
US5449602A (en) | 1988-01-13 | 1995-09-12 | Amoco Corporation | Template-directed photoligation |
US4988617A (en) * | 1988-03-25 | 1991-01-29 | California Institute Of Technology | Method of detecting a nucleotide change in nucleic acids |
CA1341584C (en) | 1988-04-06 | 2008-11-18 | Bruce Wallace | Method of amplifying and detecting nucleic acid sequences |
US5066580A (en) * | 1988-08-31 | 1991-11-19 | Becton Dickinson And Company | Xanthene dyes that emit to the red of fluorescein |
US5366860A (en) * | 1989-09-29 | 1994-11-22 | Applied Biosystems, Inc. | Spectrally resolvable rhodamine dyes for nucleic acid sequence determination |
US5188934A (en) * | 1989-11-14 | 1993-02-23 | Applied Biosystems, Inc. | 4,7-dichlorofluorescein dyes as molecular probes |
US5654442A (en) * | 1989-11-14 | 1997-08-05 | The Perkin-Elmer Corporation | 4,7-dichlorofluorescein dyes as molecular probes |
US5091652A (en) * | 1990-01-12 | 1992-02-25 | The Regents Of The University Of California | Laser excited confocal microscope fluorescence scanner and method |
US5274240A (en) * | 1990-01-12 | 1993-12-28 | The Regents Of The University Of California | Capillary array confocal fluorescence scanner and method |
US5750409A (en) * | 1991-11-18 | 1998-05-12 | Boehringer Mannheim Gmbh | Pentacyclic compounds and their use as absorption or fluorescent dyes |
WO1993019078A1 (en) * | 1992-03-17 | 1993-09-30 | Life Technologies, Inc. | Modified nucleotides |
ATE173767T1 (en) * | 1992-04-03 | 1998-12-15 | Perkin Elmer Corp | SAMPLES COMPOSITION AND METHODS |
US5470705A (en) * | 1992-04-03 | 1995-11-28 | Applied Biosystems, Inc. | Probe composition containing a binding domain and polymer chain and methods of use |
US5374527A (en) * | 1993-01-21 | 1994-12-20 | Applied Biosystems, Inc. | High resolution DNA sequencing method using low viscosity medium |
DE69433010T2 (en) * | 1993-04-12 | 2004-06-09 | Northwestern University, Evanston | METHOD FOR PRESENTING OLIGONUCLEOTIDES |
US5436134A (en) * | 1993-04-13 | 1995-07-25 | Molecular Probes, Inc. | Cyclic-substituted unsymmetrical cyanine dyes |
US5658751A (en) * | 1993-04-13 | 1997-08-19 | Molecular Probes, Inc. | Substituted unsymmetrical cyanine dyes with selected permeability |
DE4326466A1 (en) * | 1993-08-06 | 1995-02-09 | Boehringer Mannheim Gmbh | Infrared dye-labeled nucleotides and their use in nucleic acid detection |
AU1254295A (en) * | 1993-12-17 | 1995-07-03 | Perkin-Elmer Corporation, The | Uncharged polymers for separation of biomolecules by capillary electrophoresis |
US5543026A (en) * | 1994-02-07 | 1996-08-06 | The Perkin-Elmer Corporation | Real-time scanning fluorescence electrophoresis apparatus for the analysis of polynucleotide fragments |
US5565554A (en) | 1994-07-29 | 1996-10-15 | The Regents Of The University Of California | Dimeric fluorescent energy transfer dyes comprising asymmetric cyanine azole-indolenine chromophores |
DE69516415T2 (en) * | 1994-10-14 | 2000-09-14 | Stratagene La Jolla | PORPHYRINE LABELING OF POLYNUCLEOTIDES |
US5843658A (en) * | 1995-03-10 | 1998-12-01 | Hamamatsu Photonics K.K. | Method of measuring oligonucleotide decomposing activity |
US6020481A (en) | 1996-04-01 | 2000-02-01 | The Perkin-Elmer Corporation | Asymmetric benzoxanthene dyes |
US5847162A (en) * | 1996-06-27 | 1998-12-08 | The Perkin Elmer Corporation | 4, 7-Dichlororhodamine dyes |
US5863727A (en) * | 1996-05-03 | 1999-01-26 | The Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
US5800996A (en) * | 1996-05-03 | 1998-09-01 | The Perkin Elmer Corporation | Energy transfer dyes with enchanced fluorescence |
US5945526A (en) * | 1996-05-03 | 1999-08-31 | Perkin-Elmer Corporation | Energy transfer dyes with enhanced fluorescence |
US6005113A (en) * | 1996-05-15 | 1999-12-21 | Molecular Probes, Inc. | Long wavelength dyes for infrared tracing |
US6017712A (en) * | 1996-06-27 | 2000-01-25 | Lee; Linda | 4,7-dichlororhodamine dyes |
US6080852A (en) * | 1996-06-27 | 2000-06-27 | The Perkin-Elmer Corporation | 4,7-dichlororhodamine dyes |
CZ293215B6 (en) * | 1996-08-06 | 2004-03-17 | F. Hoffmann-La Roche Ag | Enzyme of thermally stable DNA polymerase, process of its preparation and a pharmaceutical composition and a kit containing thereof |
US5821356A (en) * | 1996-08-12 | 1998-10-13 | The Perkin Elmer Corporation | Propargylethoxyamino nucleotides |
US6027709A (en) * | 1997-01-10 | 2000-02-22 | Li-Cor Inc. | Fluorescent cyanine dyes |
EP0870770A1 (en) * | 1997-04-10 | 1998-10-14 | Kreatech Biotechnology B.V. | A trans-platinum based compound, a diagnostic kit comprising said compound and a method for labeling a bio-organic molecule wherein use is made of said compound |
US5770716A (en) * | 1997-04-10 | 1998-06-23 | The Perkin-Elmer Corporation | Substituted propargylethoxyamido nucleosides, oligonucleotides and methods for using same |
US6140086A (en) * | 1997-08-15 | 2000-10-31 | Fox; Donna K. | Methods and compositions for cloning nucleic acid molecules |
EP2341057A3 (en) | 1997-09-12 | 2011-11-23 | Exiqon A/S | Oligonucleotide Analogues |
US6008379A (en) * | 1997-10-01 | 1999-12-28 | The Perkin-Elmer Corporation | Aromatic-substituted xanthene dyes |
FR2769315B1 (en) * | 1997-10-03 | 2001-06-08 | Cis Bio Int | FLUORESCENT CONJUGATES OF NUCLEOSIDES OR NUCLEOTIDES, PROCESS FOR THEIR PREPARATION AND THEIR USE |
US5936087A (en) | 1997-11-25 | 1999-08-10 | The Perkin-Elmer Corporation | Dibenzorhodamine dyes |
JP2002510466A (en) * | 1998-01-23 | 2002-04-09 | アマーシャム・ファルマシア・バイオテック・インコーポレーテッド | Methods, reagent solutions and kits for DNA sequencing |
US6080868A (en) * | 1998-01-23 | 2000-06-27 | The Perkin-Elmer Corporation | Nitro-substituted non-fluorescent asymmetric cyanine dye compounds |
EP1060264B1 (en) * | 1998-02-04 | 2005-07-06 | Amersham Biosciences Corp. | Dideoxy dye terminators |
US6096875A (en) * | 1998-05-29 | 2000-08-01 | The Perlein-Elmer Corporation | Nucleotide compounds including a rigid linker |
US5948648A (en) * | 1998-05-29 | 1999-09-07 | Khan; Shaheer H. | Nucleotide compounds including a rigid linker |
US6248884B1 (en) * | 1999-06-03 | 2001-06-19 | The Perkin-Elmer Corporation | Extended rhodamine compounds useful as fluorescent labels |
DE60021395D1 (en) * | 1999-08-21 | 2005-08-25 | Amersham Biosciences Corp | TAQ DNA POLYMERASE WITH AN AMINO SUBSTITUTION IN POSITION E681 AND AN ACCORDING HOMOLOGO WITH AN IMPROVED SALT TOLERANCE, USEFUL FOR SEQUENCING DIFFICULT TEMPLATE SEQUENCES BY LOADING OR UNLOADING TERMINATORS |
US6191278B1 (en) * | 1999-11-03 | 2001-02-20 | Pe Corporation | Water-soluble rhodamine dyes and conjugates thereof |
US6221604B1 (en) * | 2000-02-07 | 2001-04-24 | Pe Corporation | Electron-deficient nitrogen heterocycle-substituted fluorescein dyes |
US6465644B1 (en) * | 2000-05-02 | 2002-10-15 | Applera Corporation | Sulfonated [8,9] benzophenoxazine dyes and the use of their labelled conjugates |
ATE431355T1 (en) * | 2000-10-11 | 2009-05-15 | Applera Corp | FLUORESCENT NUCLEOBASECONJUGATES WITH ANIONIC LINKERS |
-
2001
- 2001-10-11 AT AT01981488T patent/ATE431355T1/en not_active IP Right Cessation
- 2001-10-11 DE DE60138714T patent/DE60138714D1/en not_active Expired - Lifetime
- 2001-10-11 AU AU2002213125A patent/AU2002213125B2/en not_active Ceased
- 2001-10-11 CA CA002425663A patent/CA2425663C/en not_active Expired - Fee Related
- 2001-10-11 EP EP01981488A patent/EP1317464B1/en not_active Expired - Lifetime
- 2001-10-11 JP JP2002534329A patent/JP4741170B2/en not_active Expired - Fee Related
- 2001-10-11 US US09/976,168 patent/US6811979B2/en not_active Expired - Lifetime
- 2001-10-11 WO PCT/US2001/031822 patent/WO2002030944A2/en active Application Filing
- 2001-10-11 AU AU1312502A patent/AU1312502A/en active Pending
-
2004
- 2004-10-28 US US10/977,341 patent/US7429651B2/en not_active Expired - Fee Related
-
2008
- 2008-09-29 US US12/240,924 patent/US7687236B2/en not_active Expired - Lifetime
-
2010
- 2010-02-05 US US12/701,423 patent/US20100304381A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5986086A (en) * | 1997-06-20 | 1999-11-16 | Amersham Pharmacia Biotech Inc. | Non-sulfonated cyanine dyes for labeling nucleosides and nucleotides |
WO2001019841A1 (en) * | 1999-09-17 | 2001-03-22 | Amersham Pharmacia Biotech, Inc. | Charge-modified nucleic acid terminators |
Non-Patent Citations (1)
Title |
---|
ROSENBLUM B B ET AL: "NEW DYE-LABELED TERMINATORS FOR IMPROVED DNA SEQUENCING PATTERNS" NUCLEIC ACIDS RESEARCH, OXFORD UNIVERSITY PRESS, SURREY, GB, vol. 25, no. 22, 1997, pages 4500-4504, XP002201149 ISSN: 0305-1048 * |
Cited By (97)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2179996A1 (en) * | 2000-11-28 | 2010-04-28 | Applera Corporation | Sulfonated diarylrhodamine dyes |
EP2221347A1 (en) * | 2000-11-28 | 2010-08-25 | Applera Corporation | Sulfonated diarylrhodamine dyes |
US9939447B2 (en) | 2001-05-21 | 2018-04-10 | Monogram Biosciences, Inc. | Methods and compositions for analyzing proteins |
US7368239B2 (en) | 2003-08-29 | 2008-05-06 | Applera Corporation | Method and materials for polyamine catalyzed bisulfite conversion of cytosine to uracil |
US7371526B2 (en) | 2003-08-29 | 2008-05-13 | Applera Corporation | Method and materials for bisulfite conversion of cytosine to uracil |
US7262013B2 (en) | 2003-08-29 | 2007-08-28 | Applera Corporation | Bisulfite method |
US7534873B2 (en) | 2003-08-29 | 2009-05-19 | Applied Biosystems, Llc | Method and materials for quaternary amine catalyzed bisulfite conversion of cytosine to uracil |
JP2008501679A (en) * | 2004-06-02 | 2008-01-24 | エーエスエム サイエンティフィック, インコーポレイテッド | 2'-nitrobenzyl modified ribonucleotide |
JP2012095665A (en) * | 2004-06-02 | 2012-05-24 | Twistdx Inc | 2'-nitrobenzyl-modified ribonucleotide |
US7658288B2 (en) | 2004-11-08 | 2010-02-09 | Applied Biosystems, Llc | Bisulfite conversion reagent |
US9512125B2 (en) | 2004-11-19 | 2016-12-06 | The Regents Of The University Of California | Substituted pyrazolo[3.4-D] pyrimidines as anti-inflammatory agents |
US8642604B2 (en) | 2006-04-04 | 2014-02-04 | The Regents Of The University Of California | Substituted pyrazolo[3,2-d]pyrimidines as anti-cancer agents |
US7585868B2 (en) | 2006-04-04 | 2009-09-08 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines as kinase antagonists |
US9493467B2 (en) | 2006-04-04 | 2016-11-15 | The Regents Of The University Of California | PI3 kinase antagonists |
WO2008039997A2 (en) * | 2006-09-28 | 2008-04-03 | Applera Corporation | Nucleobase conjugates with cationic backbone linkers |
WO2008039997A3 (en) * | 2006-09-28 | 2008-05-22 | Applera Corp | Nucleobase conjugates with cationic backbone linkers |
US9359349B2 (en) | 2007-10-04 | 2016-06-07 | Intellikine Llc | Substituted quinazolines as kinase inhibitors |
US9822131B2 (en) | 2008-01-04 | 2017-11-21 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8785456B2 (en) | 2008-01-04 | 2014-07-22 | Intellikine Llc | Substituted isoquinolin-1(2H)-ones, and methods of use thereof |
US8703777B2 (en) | 2008-01-04 | 2014-04-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9216982B2 (en) | 2008-01-04 | 2015-12-22 | Intellikine Llc | Certain chemical entities, compositions and methods |
US11433065B2 (en) | 2008-01-04 | 2022-09-06 | Intellikine Llc | Certain chemical entities, compositions and methods |
US9655892B2 (en) | 2008-01-04 | 2017-05-23 | Intellikine Llc | Certain chemical entities, compositions and methods |
US8993580B2 (en) | 2008-03-14 | 2015-03-31 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US8637542B2 (en) | 2008-03-14 | 2014-01-28 | Intellikine, Inc. | Kinase inhibitors and methods of use |
US9637492B2 (en) | 2008-03-14 | 2017-05-02 | Intellikine Llc | Benzothiazole kinase inhibitors and methods of use |
US9828378B2 (en) | 2008-07-08 | 2017-11-28 | Intellikine Llc | Kinase inhibitors and methods of use |
US9629843B2 (en) | 2008-07-08 | 2017-04-25 | The Regents Of The University Of California | MTOR modulators and uses thereof |
US9096611B2 (en) | 2008-07-08 | 2015-08-04 | Intellikine Llc | Kinase inhibitors and methods of use |
US9296742B2 (en) | 2008-09-26 | 2016-03-29 | Intellikine Llc | Heterocyclic kinase inhibitors |
US9790228B2 (en) | 2008-09-26 | 2017-10-17 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8703778B2 (en) | 2008-09-26 | 2014-04-22 | Intellikine Llc | Heterocyclic kinase inhibitors |
US8697709B2 (en) | 2008-10-16 | 2014-04-15 | The Regents Of The University Of California | Fused ring heteroaryl kinase inhibitors |
US8476282B2 (en) | 2008-11-03 | 2013-07-02 | Intellikine Llc | Benzoxazole kinase inhibitors and methods of use |
US8476431B2 (en) | 2008-11-03 | 2013-07-02 | Itellikine LLC | Benzoxazole kinase inhibitors and methods of use |
US8785454B2 (en) | 2009-05-07 | 2014-07-22 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9315505B2 (en) | 2009-05-07 | 2016-04-19 | Intellikine Llc | Heterocyclic compounds and uses thereof |
US9206182B2 (en) | 2009-07-15 | 2015-12-08 | Intellikine Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US9522146B2 (en) | 2009-07-15 | 2016-12-20 | Intellikine Llc | Substituted Isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8569323B2 (en) | 2009-07-15 | 2013-10-29 | Intellikine, Llc | Substituted isoquinolin-1(2H)-one compounds, compositions, and methods thereof |
US8980899B2 (en) | 2009-10-16 | 2015-03-17 | The Regents Of The University Of California | Methods of inhibiting Ire1 |
US9181221B2 (en) | 2010-05-21 | 2015-11-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US9738644B2 (en) | 2010-05-21 | 2017-08-22 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8604032B2 (en) | 2010-05-21 | 2013-12-10 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
US8901133B2 (en) | 2010-11-10 | 2014-12-02 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9388183B2 (en) | 2010-11-10 | 2016-07-12 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8809349B2 (en) | 2011-01-10 | 2014-08-19 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9290497B2 (en) | 2011-01-10 | 2016-03-22 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US11312718B2 (en) | 2011-01-10 | 2022-04-26 | Infinity Pharmaceuticals, Inc. | Formulations of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one |
USRE46621E1 (en) | 2011-01-10 | 2017-12-05 | Infinity Pharmaceuticals, Inc. | Processes for preparing isoquinolinones and solid forms of isoquinolinones |
US9840505B2 (en) | 2011-01-10 | 2017-12-12 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1 (2H)-one and methods of use thereof |
US10550122B2 (en) | 2011-01-10 | 2020-02-04 | Infinity Pharmaceuticals, Inc. | Solid forms of (S)-3-(1-(9H-purin-6-ylamino)ethyl)-8-chloro-2-phenylisoquinolin-1(2H)-one and methods of use thereof |
US9295673B2 (en) | 2011-02-23 | 2016-03-29 | Intellikine Llc | Combination of mTOR inhibitors and P13-kinase inhibitors, and uses thereof |
US9605003B2 (en) | 2011-07-19 | 2017-03-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9056877B2 (en) | 2011-07-19 | 2015-06-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9718815B2 (en) | 2011-07-19 | 2017-08-01 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8969363B2 (en) | 2011-07-19 | 2015-03-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9546180B2 (en) | 2011-08-29 | 2017-01-17 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8785470B2 (en) | 2011-08-29 | 2014-07-22 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9115141B2 (en) | 2011-08-29 | 2015-08-25 | Infinity Pharmaceuticals, Inc. | Substituted isoquinolinones and methods of treatment thereof |
US9895373B2 (en) | 2011-09-02 | 2018-02-20 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9321772B2 (en) | 2011-09-02 | 2016-04-26 | The Regents Of The University Of California | Substituted pyrazolo[3,4-D]pyrimidines and uses thereof |
US9255108B2 (en) | 2012-04-10 | 2016-02-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8940742B2 (en) | 2012-04-10 | 2015-01-27 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US8828998B2 (en) | 2012-06-25 | 2014-09-09 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US9527847B2 (en) | 2012-06-25 | 2016-12-27 | Infinity Pharmaceuticals, Inc. | Treatment of lupus, fibrotic conditions, and inflammatory myopathies and other disorders using PI3 kinase inhibitors |
US10822340B2 (en) | 2012-09-26 | 2020-11-03 | The Regents Of The University Of California | Substituted imidazolopyrazine compounds and methods of using same |
US10131668B2 (en) | 2012-09-26 | 2018-11-20 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pYRAZINES for modulation of IRE1 |
US11613544B2 (en) | 2012-09-26 | 2023-03-28 | The Regents Of The University Of California | Substituted imidazo[1,5-a]pyrazines for modulation of IRE1 |
US9481667B2 (en) | 2013-03-15 | 2016-11-01 | Infinity Pharmaceuticals, Inc. | Salts and solid forms of isoquinolinones and composition comprising and methods of using the same |
US10329299B2 (en) | 2013-10-04 | 2019-06-25 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9751888B2 (en) | 2013-10-04 | 2017-09-05 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9828377B2 (en) | 2013-10-04 | 2017-11-28 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9359365B2 (en) | 2013-10-04 | 2016-06-07 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9775844B2 (en) | 2014-03-19 | 2017-10-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10675286B2 (en) | 2014-03-19 | 2020-06-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11541059B2 (en) | 2014-03-19 | 2023-01-03 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11944631B2 (en) | 2014-04-16 | 2024-04-02 | Infinity Pharmaceuticals, Inc. | Combination therapies |
US11110096B2 (en) | 2014-04-16 | 2021-09-07 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2015175873A1 (en) | 2014-05-16 | 2015-11-19 | Life Technologies Corporation | Cell tracking reagents and their methods of use |
EP3502693A1 (en) | 2014-05-16 | 2019-06-26 | Life Technologies Corporation | Cell tracking reagents and their methods of use |
US10253047B2 (en) | 2014-10-03 | 2019-04-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US10941162B2 (en) | 2014-10-03 | 2021-03-09 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US9708348B2 (en) | 2014-10-03 | 2017-07-18 | Infinity Pharmaceuticals, Inc. | Trisubstituted bicyclic heterocyclic compounds with kinase activities and uses thereof |
US10160761B2 (en) | 2015-09-14 | 2018-12-25 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US11939333B2 (en) | 2015-09-14 | 2024-03-26 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US11247995B2 (en) | 2015-09-14 | 2022-02-15 | Infinity Pharmaceuticals, Inc. | Solid forms of isoquinolinones, and process of making, composition comprising, and methods of using the same |
US10759806B2 (en) | 2016-03-17 | 2020-09-01 | Infinity Pharmaceuticals, Inc. | Isotopologues of isoquinolinone and quinazolinone compounds and uses thereof as PI3K kinase inhibitors |
US10919914B2 (en) | 2016-06-08 | 2021-02-16 | Infinity Pharmaceuticals, Inc. | Heterocyclic compounds and uses thereof |
US11147818B2 (en) | 2016-06-24 | 2021-10-19 | Infinity Pharmaceuticals, Inc. | Combination therapies |
WO2020132607A1 (en) | 2018-12-20 | 2020-06-25 | Life Technologies Corporation | Asymmetric rhodamine dye and use thereof in biological assays |
WO2020132487A1 (en) | 2018-12-20 | 2020-06-25 | Life Technologies Corporation | Modified rhodamine dye and use thereof in biological assays |
WO2021004379A1 (en) * | 2019-07-05 | 2021-01-14 | 南京金斯瑞生物科技有限公司 | Fluorescently labeled nucleic acid and synthesis method therefor |
CN114040919A (en) * | 2019-07-05 | 2022-02-11 | 南京金斯瑞生物科技有限公司 | Fluorescence labeling nucleic acid and synthetic method thereof |
CN111410624A (en) * | 2020-01-09 | 2020-07-14 | 江西科技师范大学 | Asymmetric naphthalene-pyrrole hybrid diarylethene compound and application thereof |
WO2022020723A1 (en) * | 2020-07-23 | 2022-01-27 | Life Technologies Corporation | Energy transfer dye conjugates for use in biological assays |
EP4089098A1 (en) * | 2021-05-10 | 2022-11-16 | Miltenyi Biotec B.V. & Co. KG | Fret dye labeled reversible nucleotide terminators and their use in sequencing of dna |
Also Published As
Publication number | Publication date |
---|---|
US20020102590A1 (en) | 2002-08-01 |
EP1317464A2 (en) | 2003-06-11 |
US6811979B2 (en) | 2004-11-02 |
US7429651B2 (en) | 2008-09-30 |
US20050250119A1 (en) | 2005-11-10 |
CA2425663C (en) | 2009-12-29 |
US20100304381A1 (en) | 2010-12-02 |
DE60138714D1 (en) | 2009-06-25 |
WO2002030944A3 (en) | 2003-01-16 |
US20090092986A1 (en) | 2009-04-09 |
CA2425663A1 (en) | 2002-04-18 |
JP2004529070A (en) | 2004-09-24 |
US7687236B2 (en) | 2010-03-30 |
ATE431355T1 (en) | 2009-05-15 |
AU2002213125B2 (en) | 2007-11-22 |
JP4741170B2 (en) | 2011-08-03 |
EP1317464B1 (en) | 2009-05-13 |
AU1312502A (en) | 2002-04-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2002213125B2 (en) | Fluorescent nucleobase conjugates having anionic linkers | |
AU2002213125A1 (en) | Fluorescent nucleobase conjugates having anionic linkers | |
JP4942150B2 (en) | Fluorescein dyes substituted with electron-deficient nitrogen heterocycles | |
CA2358923C (en) | Water-soluble rhodamine dyes and conjugates thereof | |
AU707242B2 (en) | Asymmetric benzoxanthene dyes | |
ES2225468T3 (en) | CYANINE-BASED COLORS THAT MODIFY MOBILITY. | |
EP1165694B1 (en) | 4,7-dichlororhodamine dyes useful as molecular probes | |
CA2382663A1 (en) | Uv excitable fluorescent energy transfer dyes | |
AU2008200830A1 (en) | Fluorescent nucleobase conjugates having anionic linkers | |
WO2009131805A1 (en) | Nucleic acid terminators incorporating a cationic moiety and methods for their use | |
WO2008039997A2 (en) | Nucleobase conjugates with cationic backbone linkers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PH PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002213125 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001981488 Country of ref document: EP Ref document number: 2002534329 Country of ref document: JP Ref document number: 2425663 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 2001981488 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
ENP | Entry into the national phase |
Ref document number: 2002213125 Country of ref document: AU Date of ref document: 20011011 Kind code of ref document: B |